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Abstract  
 
Heart transplantation outcome is related to effects of immunological and no 
immunological factors. The major immunological factors are the HLA, the 
autoimmunity and the inflammation, while the non-immunological factors 
include among other the hypertension, diabetes, immunosuppressive therapies, 
cancer and infections. Infectious complications represent a significant source of 
morbidity and mortality in heart transplantation recipients. However, few 
studies have been focused on the incidence and the types of infection in 
patients awaiting heart transplantation and the impact of pre-transplantation 
infections on the early post-transplantation period. Often these are 
opportunistic infections due to virus, bacteria and fungi that can be difficult to 
identify, to treat, and can be lethal in the immunosuppressed patients. Most 
post-transplantation infections represent reactivation of latent or quiescent 
infections that had been contracted prior to transplantation. Recently, several 
evidences have showed the incidence of B. henselae infections in solid organ 
transplantation recipients. B. henselae infections are responsible for a widening 
spectrum of human diseases, ranging from self-limited to life-threatening and 
show different course and organ involvement due to the balance between host 
and pathogen. The role of the host immune response to B. henselae is critical in 
preventing progression to systemic disease. Indeed, in immunocompromised 
patients, such as solid organ transplanted subjects, B. henselae infection results 
in severe disseminated disease and pathologic vasoproliferation with 
involvement of different organs mainly due to vasoproliferative lesions. 
Furthermore, B. henselae can persist in primary niche prior to blood-stage 
infection. In vitro and in vivo studies have demonstrated that endothelial 
progenitor cells are able to internalize B. henselae and they are eligibile as 
primary niche. Susceptibility to infections and many other human diseases 
arises through the complex interaction between environmental and host genetic 
factors including the HLA molecules. In our study, we have found a B. 
henselae significant antibody positivity rate of 21% in patients awaiting heart 
transplantation enrolled in our Regional Reference list for organ 
transplantation. We have demonstrated a significant correlation between the B. 
henselae infection and the presence of HLA-B*35 allele and a significant 
impairment of number of circulating endothelial progenitor cells in patients 
with advanced heart failure. In addition, we have also evaluated the tissue 
damage in a model of immunocompromised mice infected with B. henselae by 
revealing a strong deposition of collagen after B. henselae infection and an 
increase of endothelial progenitor cell number that can suggest an involvement 
of these cells in the immune response of mice infected but also in the triggering 
the vasoproliferative process.  
Our retrospective observational study, although performed on a small number 
of patients only in pre-transplantation time suggests that B. henselae, together 
with other emerging bacteria, should be included as a routine analysis in the list 
of opportunistic infections.   
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1.0 Background  
1.1.0 Cardiovascular disease and HTx 
Coronary heart disease, peripheral arterial disease, and endocarditis are 
the most relevant cardiovascular diseases (World Health Organization, 2011). 
Several are the causes of cardiovascular diseases but atherosclerosis and 
hypertension remain the most common (Mathers and Loncar 2006). Despite 
major risk factors for cardiovascular diseases have been firmly established, still 
a quarter of people presenting the disease do not show any of the known 
cardiovascular risk factors (Magnus and Beaglehole, 2001). There is 
considerable interest to look for novel components affecting cardiovascular 
health, especially for those that could improve global cardiovascular risk 
prediction. Based upon the immuno-inflammatory response elicited by 
infectious disease, the microbiological contribution to atherosclerosis, the 
pathological basis of the vast majority of cardiovascular diseases, represents a 
long-standing controversy (Nieto 2002; Rosenfeld and Campbell 2011). An 
abundance of data suggests that several infectious agents, as Chlamydophila 
pneumoniae, Helicobacter pylori, Cytomegalovirus might contribute to 
atherosclerotic vascular diseases (Chatzidimitriou et al. 2012). The finding that 
the bacterium Bartonella henselae can infect endothelial progenitor cells 
(EPCs) (Salvatore et al., 2008) suggests an alternative mechanism for 
infectious diseases to promote cardiovascular disease. Therefore, this recent 
evidence, by connecting infective agents, regenerative medicine, and 
cardiovascular disease, highlights different perspectives about such a blurred 
scenario. 
Heart transplantation (HTx) is the only therapeutical option for patients with 
end-stage heart failure (Lund et al. 2013) but it is available only to a minority 
of patients due to the low heart donors availability and the contraindications or 
risk factors in several patients with heart failure (Hunt and Haddad 2008). 
Cardiomiopathy has been the leading cause for HTx, followed by coronary 
artery disease (Stewart et al. 2014). In Italy, patients on awaiting HTx have a 
waiting list time of about 2.3 years (http://www.trapianti.salute.gov.it/) during 
which a progressive clinical deterioration and an annual mortality of 8–10% 
can occur. Indeed, every year 10–15% of patients awaiting HTx are withdrawn 
from the waiting list because they are no longer eligible candidates. The 
availability of donor organs remains a limiting factor that results in an 
increased time on waiting list with higher incidence of mortality (Picascia et al. 
2014). This requirement has led to continuous demand in use of mechanical 
ventricular assist device technologies for the management of patients on 
waiting for HTx as a bridge to transplantation by improving survival and 
quality of life of patients with refractory heart failure (Boothroyd et al. 2013).  
The identification of patients eligibile for HTx and their inclusion in  waiting 
list is a complex process that requires a multidisciplinary approach to evaluate 
for each patient the benefit/risk of the transplantation (Crudele et al. 2011, 
Picascia et al. 2014) The goal of HTx is to increase the length and quality of 
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life and therefore the perioperative risk, the quality of the transplanted organs 
as well as the risks of immunosuppressive therapy and the donor-recipient 
compatibility are all parameters that must be taken into account (Crudele et al. 
2011). Other important variables that affect the prognosis and the worsening of 
clinical conditions are represented by infections that can worsen after 
transplantation and/or increase the likelihood and degree of complications in 
the postoperative period.  
Furthermore, after the introduction of cyclosporine in the early 1980s, many 
advances have been made in the diagnosis and treatment of graft dysfunction, 
in rejection and infection leading to a significant improvement in patient and in 
graft survival, at least up to 5 years after transplantation (Hunt and Haddad 
2008). However, late complications such as cardiac allograft vasculopathy and 
adverse effects due to prolonged immunosuppressive therapies continue to 
influence and reduce the long-term survival (Hunt and Haddad 2008). In 
particular, the early and strong induction immunosuppressive treatment and the 
long-term maintenance immunosuppressive therapy affect transplantation 
outcome and the most important side effects are an increased susceptibility to 
infection and cancer. However, the causes of death were stable in the last years 
with prevalence of graft failure followed by infections (Lund et al. 2013, 
Salvadori and Bertoni 2014). 
 
1.1.1 Infection and HTx 
To date, only few studies have been focused on the incidence and types 
of infection in patients with terminal heart failure, although the role of 
infections in hospital admissions is well known in these patients (Fishman and 
Issa 2010, Fernández-Ruiz et al. 2014). Although it is recognized that post-
transplantation infections affect outcome in HTx recipients and there are many 
known risk factors for infections especially in the early post-transplantation 
period, there are no work that describe the epidemiology of infections in 
patients awaiting HTx, and the impact of pre-transplantation infections on the 
early post-transplantation period is not well known (Kotton 2007). There are 
few studies performed on liver transplantation patients with controversial 
results. Sun (2011) has found no differences in mortality of liver 
transplantation patients at 90 and 180 days with and without a history of 
bacterial infection in the year prior to transplantation (Sun et al. 2011). 
Conversely, Kim (2008) has described colonization or infection prior to liver 
transplantation as a predictor of death in the first 3 months after transplantation 
(Kim et al. 2008). 
Infectious complications are frequent, but are no longer the leading cause of 
death. However, late infections are still a threat to long-term graft survival in 
transplanted patients. Bacterial infections are the most common which usually 
appear in the first month or after one year following transplantation (Sun et al. 
2011). The overall incidence of fungal infections including pulmonary 
aspergillosis has decreased considerably in recent years (2%-15%), but 
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associated mortality remains high. Cytomegalovirus is the most important 
pathogen in HTx, affecting 7%-35% of patients. Although antiviral 
prophylactic and pre-emptive therapy have reduced the incidence of acute 
cytomegalovirus disease, the role of this microorganism in the allograft 
vascular disease, the most common cause of death in these patients, is a cause 
for concern. Toxoplasmosis, a particularly severe entity in HTx recipients, has 
decreased with the use of routine prophylaxis in seronegative recipients 
(Fernández-Ruiz et al. 2014). In addition, driveline and blood stream infections 
are often a common complication related to ventricular assist device, especially 
in long-term support with a prevalence ranging from 18 to 59% (Athan et al. 
2012, Gordon et al. 2013, Rosenfeldt et al. 2014). In some reports, infections in 
HTx are associated with significant morbidity and mortality whereas in other 
studies outcome are not affected.  
Several evidences have reported that about the infectious complications, the 
endocarditis following HTx are unique among solid organ recipients because it 
is the transplanted organ that becomes infected (Sherman-Weber et al. 2004). 
The high incidence of endocarditis is related also to catheter and other blood 
stream infections, donor heart contamination, and suppression of cell-mediated 
immunity. Unfortunately, the prognosis for post-HTx infective endocarditis is 
very poor. Moreover, active bacterial infections in the pre-transplantation time 
are usually considered to be an absolute contraindication to HTx (Macdonald 
2008, Durante-Mangoni et al. 2011). However, HTx was resulted as salvage 
treatment for intractable infective endocarditis (Aymami et al. 2014). Thus 
infective endocarditis may be the cause for HTx but also a post-transplantation 
complication. 
Although in recent years many advances in the immunosuppressive therapy, in 
the surgical techniques, in the organ preservation as well as in the overall 
management of transplantated patients have been made, the infectious 
complications remain a problem, yet (Crudele et al. 2011). However, the 
effects of bacterial, fungal, viral and parasitic infections after transplantation 
depend on the degree of immunosuppression,  type of organ transplantated, 
host factors, as well as post-transplantation period. In the last years, several 
cases of disseminated B. henselae infection have been described in patients 
underwent to solid organ transplantation including kidney and liver and to a 
lesser degree heart and lung. 
 
1.1.2 Natural history of Bartonella infections  
 
Bartonella spp are facultative intracellular pathogens, gram-negative, 
aerobic, pleiomorphic bacilli that cause prolonged intraerythrocytic bacteremia 
and systemic infections in their hosts. To date, more than 30 Bartonella spp 
have been isolated from humans and animals around the world. Bartonella spp 
have a natural cycle of infection common to many pathogens transmitted by 
vectors which begins with the inoculation of the pathogens in a mammalian 
reservoir host usually by bloodsucking arthropods (Dehio 2005). After 
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inoculation, Bartonella spp not colonize directly the erythrocytes but remain in 
a primary niche. Following this step, the Bartonella spp are spread into 
bloodstream and they are able to infect the erythrocytes through several steps 
ranging from adhesion, invasion and persistence in these cells by enabling a 
continuous vector transmission (Schülein et al. 2001). This strategy of infection 
provides to bacteria a sanctuary to defend themselves from the host immune 
system. During the cycle, the vectors allow to transmit the bacteria from the 
reservoir host, in which the bacteria cause a chronic intraerythrocytic 
bacteremia, to new susceptible hosts. There is usually a specific association 
between the natural host, vectors, and Bartonella spp that influences the 
spectrum of natural or incidental hosts and the geographic distribution of the 
organisms (Schülein et al. 2001, Boulouis et al. 2005). A wide range of animals 
serve as reservoirs for Bartonella spp but humans are the only known reservoir 
for Bartonella bacilliformis and Bartonella quintana. Several species of the 
genus Bartonella cause human infections including Bartonella henselae, 
Bartonella quintana and Bartonella bacilliformis. B. henselae or B. quintana 
provoke pathologies with a limited morbidity while B. bacilliformis is unique 
as a deadly pathogen causing Carrion’s disease, which can kill more than 80% 
of the patients during its acute phase but it is restricted to limited geographic 
area (Maguiña et al. 2009). The domestic cats are the reservoir of B. henselae 
and the presence of the bacterium in cat fleas has been described. B. henselae is 
transmitted either through the bite, scratch, or lick of an infected kitten or cat. 
Transmission of B. henselae to reservoir occurs via arthropod vectors such as 
Ctenocephalides felis. Furthermore, the multistep strategies of Bartonella 
infection imply that host specificity might be a very complex process in which 
each step can be modulated at molecular level (Pulliainen and Dehio 2012). 
 
1.1.3 B. henselae epidemiology 
 
The different geographic diffusion of the Bartonella spp is related to 
distribution of their hosts or vectors. Indeed, the species with an ubiquitously 
distribution such as B. quintana and B. henselae have selected hosts (people 
and cats) and vectors (body lice and cat fleas) with a worldwide distribution. 
(Harms and Dehio 2012). Bartonella spp. are currently classified as re-
emerging pathogens, since various species are increasingly found to elicit 
human disease, most likely due to changes in human society and medical 
practice but also thanks to improved diagnostic tools.  
Human Bartonella infections have been reported from several geographic area, 
including Europe, but the seroprevalence of antibodies to B. henselae have 
shown a high degree of variation and the antibody prevalence against B. 
henselae in the world may differ in various regions (Mogollon Pasapera et al. 
2009; Sun et al. 2010). Epidemiological human studies have greatly increased 
in the past decade and a high degree of variation in the prevalence of antibodies 
to B. henselae were found in several studies (Vorou et al. 2007; Pandak et al. 
2009, Pitassi et al. 2015). Moreover, the seroprevalence of antibodies against 
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B. henselae among blood donors and otherwise healthy individuals, has been 
shown to ranged from 0,6 to 61,6% and 0% to 57% respectively (da Costa et al. 
2005, Schiellerup et al. 2004, Zarkovic et al. 2007). It was demonstrated a high 
frequency of serologic evidence of past B. henselae infection, in young Italian 
children, affected by various diseases, apparently free of any clinical features 
suggesting infection (Mansueto et al. 2012). B. henselae infection is frequent in 
Tuscany and probably underdiagnosed due to the high frequency of atypical 
onset of the clinical manifestations. In particular, B. henselae infection is 
common among children in central Italy, occurs early in life, in most cases is 
asymptomatic and resolves spontaneously (Massei et al. 2000 and Massei et al. 
2003, Brunetti et al 2013). 
 
1.1.4 Clinical aspects of B. henselae infection in humans 
 
B. henselae causes several clinical manifestations in humans but the 
pathological response and the clinical manifestations of infection are primarily 
determined by the  immune status of the infected human (Resto-Ruiz et al. 
2003, Kaiser et al. 2011). These bacteria are rapidly becoming prominent as 
emerging pathogens causing both acute or chronic infections and vascular 
proliferative or suppurative manifestations (Mosepele et al. 2012). B. henselae 
infection may cause a variety of human diseases, often symptomless, with 
different evolution and organ involvement due to the balance between host and 
pathogenic factors (Mogolon-Pasapera et al. 2009). B. henselae shows 
pathogenic characteristics such as the ability to invade and lyse red cells, 
causes a persistent bacteremia and induces endothelial cell proliferation. 
Usually, the response to infection is granulomatous in immunocompetent and 
vasculoproliferative in immunodeficient individuals. Two manifestations of B. 
henselae infection include Cat Scracht Disease (CSD) and Bacillary 
angiomatosis-peliosis (Zangwill et al. 2013) (Figure 1). The direct 
identification of B. henselae is difficult due to its slow growing characteristic 
and, therefore, usually delayed. Unlike molecular and histological methods 
which require a tissue sample, the serological assays utilize only a small blood 
sample for a reliable diagnosis. Therefore, diagnosis of B. henselae is mainly 
based on serological methods (IgM, IgG detection) for their ease and fastness 
(Zangwill et al. 2013). 
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Figure 1. Natural history of B. henselae in both immunocompetent and 
immunocompromised host. B. henselae infects a variety of mammals (e.g. cats, 
dogs and humans) and is transmitted by hematophagous insects. B. henselae 
causes several clinical manifestation in immunocompromised and 
immunocompetent hosts. 
 
1.1.5 Cat Scracht Disease 
 
In immunocompetent subjects, these bacteria often cause self-limiting 
infections usually with fever and regional lymphadenopathy, known as CSD, 
which can resolve spontaneously without treatment (Zangwill et al. 2013). 
CSD is a usually self-limiting lymphadenitis with long-lasting swelling of the 
lymphonodes that drain the primary inoculation site and with an erythematous 
papule followed by enlargement of lymph nodes at the inoculation site that can 
persist also for 12-24 months. After few weeks, the lymph nodes regress but in 
10% of patients the lymphadenitis may become suppurative. The characteristic 
histological change in CSD is an inflammatory granulomatous process with 
central microabscess surrounded by macrophages and rare giant cells. 
Interestingly, only small number of bacteria have been isolated from 
lymphonodes supporting the idea that the clinical manifestations are related to 
immune reaction rather to the pathogen (Prutsky et al. 2013). Additional 
complications, often in children such as rash, hepatosplenomegaly, lytic bone 
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lesions, and deep lymphadenitis may also occur. CSD has been reported 
worldwide and seem to be the most common B. henselae infection in people 
today, occurring with a seasonal incidence especially in children perhaps 
because they have more likely to have contact with cats. Between 1 and 2% of 
people with CSD will suffer of neuroretinitis, which includes disk edema and 
exudates of the macula (Zangwill et al. 2013). In the 1-2% of cases, overall 
neurological complications can occur including encephalopathy and status 
epilepticus. Relapsing or systemic infections might be treated with antibiotics. 
However, a recent meta-analysis study including randomized controlled trials 
and observational studies demonstrated that antibiotics failed to significantly 
affect the cure rate or the time required to achieve a cure (Prutsky et al. 2013). 
It remains unclear whether antibiotic treatment of localized CSD reduces the 
risk of developing systemic diseases (Angelakis and Rouldt 2014). Diagnosis 
of B. henselae infection can be confirmed by detection of antibodies in the 
serum of patients, by histopathological examination of lymphonodes or tissue 
biopsy or by molecular detection of DNA. To date, serodiagnosis by 
immunofluorescent assay (IFA) is the gold standard for the diagnosis of 
present and previous infections. 
 
1.1.6 Bacillary angiomatosis 
 
In immunocompromised patients, B. henselae results in severe 
disseminated diseases and pathologic vasoproliferation, known as bacillary 
angiomatosis and bacillary peliosis, that most commonly involve skin or 
lymphonodes and liver or spleen, respectively (Mosepele et al. 2012).  
Bacillary angiomatosis lesions are the most common manifestations of B. 
henselae infection in immunocompromised patients such as HIV or 
transplanted patients characterized by cutaneous nodular vascular lesions and 
compromising of other organs including heart, spleen, kidney, bone and central 
nervous system (Kaiser et al. 2011, Orsag et al. 2015). Similar lesions are seen 
also in both bacillary peliosis and splenitis. Bacillary angiomatosis is clinically 
manifested by the formation of vascular tumors that begin with one or more 
erythematous papules and they are due to the formation of blood vessels by 
sprouting of pre-existing vessels for the continued presence of bacteria in the 
tumor lesions (Pullinaiem and Dehio 2012, Angelakis and Roult 2014). Indeed, 
the lesions are characterized by proliferating endothelial cells, bacteria and 
mixed infiltrates of macrophages/monocytes and polymorphonuclear 
neutrophils. Histologically, these lesions are characterized by the presence of 
circumscribed proliferation of capillary structures containing epithelial cells, 
histiocytes and infiltrated neutrophils. These vasoproliferative lesions are 
indicative of chronic inflammation as consequence of an acute inflammatory 
reaction triggered by B.henselae infected endothelium. In general, an acute 
inflammatory response induces activation of endothelium that results in the 
release of proinflammatory chemoattractants and in the establishment of 
receptor-ligand interactions between endothelium activated and circulating 
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polymorphonuclear neutrophils (Dehio 2008; Kempf et al. 2005). 
Epidemiological risk factor analysis showed the cat contact in 84.6% cases of 
the B. henselae infected patients (Angelakis and Rouldt 2014).  
 
1.1.7 Endocarditis and B. henselae 
 
B. henselae bacteremia causes endocarditis, primarily in people with 
existing heart valve abnormalities. Indeed, B. henselae has been isolated from 
native aortic valve tissue of individuals affected by infective endocarditis as 
agent of blood culture-negative endocarditis  (Hoffman et al. 2007, Chomel et 
al. 2009, Khalighi et al. 2014). B. henselae causes a typical endocarditis 
diagnosed using the Duke criteria showing vegetations detected by 
echocardiography (Fournier et al.  2010). A recent study and several clinical 
trials reported that 24% cases of blood culture-negative endocarditis were 
caused by B. henselae (Houpikian and Raoult 2005, Dreier et al. 2008, 
Tsuneoka et al. 2010, Lamas Cda et al. 2013). The diagnosis of infective 
endocarditis can be difficult for the atypical presentation and negative blood 
cultures. Patients show to have pre-existing heart valve diseases that promote 
the development of infective endocarditis and do not have a history of CSD. B. 
henselae causes significant destruction of the valves characherized by 
mononuclear cell inflammation, extensive fibrosis, large calcification leading 
to valvular surgery (Houpikian and Raoult 2005). In addition, B. henselae in 
patients with valvular diseases can induce various clinical presentations such as 
bacteraemia, hepatic or splenic diseases, encephalitis, cardiopathy and 
myocarditis (Gouriet et al. 2007). All these studies have emphasized as several 
heart diseases can be caused from uncultured bacteria such as B. henselae and 
these infections are very often undiagnosed. Endocarditis, myocarditis, dilated 
cardiomiopathy may indicate the bacterial origin of the diseases and therefore 
the detection of significant titres of specific antibodies allows to identify the 
origin of the disease (Million et al. 2010). At this regard, DNA of B. henselae 
was detected in aortic valves of patients undergoing to HTx suggesting that 
among patients with cardiac disease, infections caused by B. henselae should 
be tested (Nilsson et al. 2005, Maczka et al. 2011). A recent study have 
demonstrated the need of HTx as final treatment in patients with infective 
endocarditis with extensive perivalvular lesions and end-stage heart failure 
(Aymami et al. 2014). 
 
1.1.8 B. henselae infection in transplanted patients 
 
In the last years, several cases of disseminated B. henselae infection 
with manifestation of  bacillary angiomatosis and peliosis have been described 
in patients underwent to solid organ transplantation including kidney and liver 
and to a lesser degree heart and lung. (Juskevicius et al. 2004, Psarros et al. 
2012). This distribution of bartonellosis is representative of the frequency of a 
particular transplanted population rather than the risk of B. henselae-mediated 
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disease in a particular type of transplantation. Furthermore, only 28% of the 
cases of bartonellosis were aged <18 years of age contrarily to 
immunocompetent patients in whom B. henselae infection occurs mostly in 
children and adolescents and rarely in older persons (Zangwill et al. 2013). The 
transplanted patients showed disseminated infection differently to B. henselae 
infection in immunocompetent patients in which usually the only clinical 
manifestation is the CSD. The clinical features of B. henselae infection in 
transplanted patients are variable and include fever and lymphadenopathy, 
pulmunary nodules, ocular and skin lesions, osteomyelitis, focal access and 
hepatosplenic disease (Rheault et al. 2007). The biopsies of lesions showed 
pathological findings similar to those observed in immunocompetent hosts 
such as granuloma and suppurative lesions but also vasoproliferative lesions 
which are found in lymphonodes, liver, skin and bone marrow. In addition, the 
immunocompromised patients are more likely to develop B. henselae 
bacteremia or other systemic manifestations that can occur at followed to 
spreading of bacilli in the liver, spleen, and cardiac valve triggering the 
vasoproliferative lesion as bacillary angiomatosis/peliosis (Rostad et al. 2012, 
Moulin et al. 2012, Poudel et al. 2014). Interestingly, in immunocompetent 
subjects B. henselae causes a long-lasting bacteremia while in 
immunodeficients, an alteration of innate and adaptive immunity promotes 
systemic manifestations due to the difficulty of limiting the infection. The 
major risk factor for B. henselae infection is the contact with cats. Patients with 
disseminated bartonellosis developed disease at different time of 
transplantation. In particular, patients developing earlier disease were more at 
risk of dissemination due to greater immunosuppression. Indeed, the liver 
transplanted patients have showed a disease earlier post-transplantation 
because these patients are underwent to a greater degree of immunosuppression 
(Psarros et al. 2012). Immunosuppressive therapy at which transplanted 
patients are underwent is a risk factor for bacillary angiomatosis and peliosis 
due to B. henselae. However, there are no clear relationship between the 
development of disseminated bartonellosis and a particular immunosuppressive 
therapy. 
Several studies have shown that B. henselae tend to cause vasoproliferative 
lesions rather granuloma in HIV patients suggesting that T-cell response of 
host can play a pivotal role in the control of B. henselae infection. Indeed, most 
of immunosuppressive drugs used in solid organ transplantation target the 
cellular-mediated immune response, specifically T cells including anti-
thymocyte globulin, anti-CD3 antibodies and anti-interleukin-2 receptor that 
are utilized in the induction phase of immunosuppression. In addition drugs 
used during the maintenance phase such as cyclosporine or tacrolimus affect 
the activation, the proliferation and the differentiation directly or indirectly of 
T cells (Kuypers et al. 2010).  
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1.2.0 Strategies of B. henselae infection: invasion and intracellular 
colonization of erythrocytes 
 
B. henselae has been demonstrated to establish chronic intraerythrocitic 
bacteremia in human (Minnick et al. 2009) (Figure 2). However, B. henselae 
not causes an immediate infection of red blood cells but can persist in a 
primary niche prior to blood-stage infection (Schülein et al. 2001). Moreover, 
the prolonged persistence intraerythrocytic of B. henselae is a essential aspect 
of its pathogenicity (Dehio 2001). The erythrocytes cannot to present bacterial 
antigens at immune system due to the lack of major histocompatibilty on their 
surface and in these cells the bacteria replicate. Unlike of nucleated cells, 
during the bacterial entry, a small extracellular factor deformin induces 
indentations of the erythrocytic membrane in which bacteria might localize 
prior to their internalization. B. henselae  replicates in the endocytic vacuoles 
and persists for the lifetime of the erythrocytes which increase the likelihood 
for its spread through blood-feeding insects. 
 
 
 
Figure 2: Steps of blood-stage infection by Bartonella spp. in their mammalian 
host. The infection results in colonization of primary niche followed by 
binding, invasion, replication and persistence in erythrocytes. The coincidental 
re-infection of primary niche and the efficient transmission to other hosts 
mediated by ectoparasites occurs. 
 
1.2.1 Cellular characteristics of primary niche 
 
Although several studies have highlighted the main pathogenic 
mechanisms of B. henselae infection, to date it is still unclear what is the 
primary niche of the bacterium in vivo (Schülein et al. 2001, Dehio 2008, 
Okujava et al. 2014). Several evidence in vivo and in vitro have reported that 
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endothelial cells due to a strong interaction and proximity to the circulation can 
represent an important target of B. henselae and are eligible to be part of the 
primary niche (Dehio 2005). However, other cells as migratory cells may play 
a crucial role in the establishment of B. henselae infection due to the bacterial 
need to be transported in the host. The involvement of lymph nodes during B. 
henselae infection suggests that lymphocytes or mononuclear phagocytes could 
be the vehicles of B. henselae transport by promoting the migration of 
pathogen in the tissue and vasculature areas (Dehio 2005). In particular, three 
loci have been proposed as the primary sites of infection: extracellular matrix, 
bone-marrow stem cells and mature endothelial cells.  
Other studies have proposed hematopoietic progenitor cells (HPCs) as primary 
niche suggesting that B. henselae could infect erythrocyte progenitors and then 
enter in the bloodstream coincident with their maturation (Mandle et al. 2005). 
However, it seem evident that the infection of primary cells in vivo could 
contribute to re-infection of the bloodstream and to dissemination of the 
pathogen. Several in vitro studies showed that B. henselae can invade 
endothelial cells, macrophages and monocytes including microglial cells 
(Musso et al. 2001). On this basis, the ability to invade endothelial cells could 
strongly alter the maintenance of vascular homeostasis and determine the 
pathogenic mechanisms of B. henselae. 
   
1.2.2 Adhesion and invasion of endothelial and nucleated cells  
 
The interaction of B. henselae with endothelial and other nucleated cells 
occurs by several mechanisms including cellular invasion, activation of NFkB 
and hypoxia-inducible transcription factor (HIF-1) signaling. The first step is 
the adherence of bacterium to the extracellular matrix and to the host cell 
membrane through components of surface structures of B. henselae identified 
as trimeric autotransporter adhesions (TAAs). These non-fimbrial outer 
membrane adhesion proteins belong to the type V secretion system (T5SS) 
(Pullinaiem and Dehio 2012). The Bartonella adhesion A (BadA) belongs to 
the TAAs family and it binds some components of extracellular matrix of host 
cells including collagen, laminin and 1-integrin. The uptake of B. henselae in 
endothelial and other nucleated cells is related to actin-enriched cell membrane 
protrusions of the host cell (Figure 3). The internalization in endhotelial cells 
occurs through two different processes enabling either the uptake of single 
bacteria by a zipper-like pathway and the aggregation of bacteria in large 
structures defined as invasoma. Single bacteria are internalized in Bartonella-
containing vacuoles (BCVs) localized in a perinuclear area and that fail to 
acidify and to fuse with lysosomes due to the lack of lysosomal markers (Kyme 
et al. 2005). The BCVs-mediated endocytosis is blocked after injection of 
Bartonella effector proteins (BepA-BepG) in the host cells (Truttmann et al. 
2011, Eicher and Dehio 2012). Invasoma formation is a multipstep process that 
involves bacterial adherence, effector translocation, aggregation and 
internalization by an F-actin- and integrin1-dependent mechanism (Truttmann 
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et al. 2011). Noteworthy, the invasome formation is a slower process than the 
BCVs development. 
 
 
 
Figure 3. Adhesion of B. henselae on target cell. BadA, a trimeric 
autotransporter adhesion mediates the adhesion on target cells and a direct or 
indirect relationship between the attachement to 1-integrin and the HIF or 
NF-B was supposed.  
 
1.2.3 Virulence factors of B. henselae 
 
Virulence factors of B. henselae involved in the infection, replication 
and persistence in host cells have been identified including the Type IV 
Secretion System (TFSS), LPS, GROEL, and BadA (Vayssier-Taussat et al. 
2010, Siamer and Dehio 2015). The TAAs are virulence factors of Gram-
negative bacteria that bind host proteins on cell surface (Harms and Dehio 
2012) (Figure 4).  
 
BadA 
BadA is a trimeric autotrasporter of B. henselae involved in the adhesion to 
endhotelial cells by targeting 1-integrin and by binding to extracellular matrix 
(Figure 3). BadA promotes a proangiogenic transcriptional program in host 
cells. The activation of both NFkB and HIF-1 was demonstrated to be 
dependent on BadA. Kempf (2005) has reported that NFkb and HIF-1 
activation are induced by the interaction between 1-integrin and extracellular 
matrix proteins by leading to the expression of proangiogenic genes such as IL-
8 by NFkB pathway (Kempf et al. 2005). Thus, the interaction with BadA 
would to be involved in the activation of pro-angiogenic program by activating 
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HIF-1. BadA was demonstrated to protect B. henselae from phagocytosis 
macrophages-mediated (Riess et al. 2004). 
 
VirB-like T4SS and Beps 
T4SS are complex molecular machineries that mediate the conjugation process 
and traslocation of effector proteins in target cells (Dehio 2008). 
The VIRB/D4 T4SS of B. henselae translocates Beps in the host cells 
subverting their functions to support the bacteria. The Beps complex shows a 
modular domain with the N-terminal FIC (filamentation induced by cyclic 
AMP) that mediates the interaction with the host and a C-terminal composed 
by a Bep intracellular delivery (BID) domain. Seven Beps are known. The BID 
domain can trigger a strong antiapoptotic and proangiogenic response 
(Scheidegger et al. 2011). Some Beps such as BepG and BepC are involved in 
the invasome pathway by inhibiting the endocytic uptake of B. henselae and by 
promoting the aggregation of bacteria (Rhomberg et al. 2009). Schmid (2006) 
has found that BID domain display an antiapoptotic activity and Beps 
participate to proinflammatory activation of endothelial cells by an increase of 
NFkB activation, ICAM-1 expression and IL-8 secretion. Noteworthy, BadA 
antibodies are detected in the sera of patients with B. henselae infection 
(Schmid et al. 2006). 
 
 
 
Figure 4. VirB/D4 T4SS and Beps complex. VirB/D4 T4SS contributes to B. 
henselae virulence by translocating Beps in host cells subverting cellular 
function. 
 
1.2.4 B. henselae and mechanism of angiogenesis 
 
The colonization of vascular endothelium and the persistence in 
endothelial cells are crucial steps for the pathological angiogenesis, the 
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activation of pro-inflammatory processes and the vasculoproliferative disorders 
that are triggered from B. henselae. In close proximity of proliferating 
endothelium, bacterial aggregates and dispersed bacteria can be found and the 
lesions are infiltrated by phagocytes such as macrophages and neutrophils 
(Pullinaiem and Dehio 2012). To date, it is supposed that B. henselae may 
cause vasculoproliferative disorders through several different mechanisms 
including NFκB-dependent proinflammatory activation, direct proliferation of 
endothelial cells, inhibition of endothelial cell apoptosis, and stimulation of 
angiogenesis through growth factors produced from peripheral cells (Kaiser et 
al. 2011).  
The infiltration of neutrophils in the vasoproliferative lesions after B. henselae 
infection indicates a proinflammatory cascade NF-kB-mediated. Indeed, 
endothelial cells infected with B. henselae have shown an up-regulation of 
adhesion molecules such as E-selectin, ICAM-1 and the release of chemokines 
including IL-8 and activation of NFκB (Fuhrmann et al. 2001). Even if the role 
of the host inflammatory response to B. henselae pathogenesis is not well 
understand, several evidence seem to suggest that the bacteria can use this 
mechanism to attract key regulators of angiogenesis such as macrophages to 
the sites of infection, which secrete pro-angiogenic molecules and growth 
factors (Fuhrmann et al. 2001) (Figure 5). 
The proliferation and migration of endothelial cells are crucial steps of the 
angiogenesis process stimulated by B. henselae and depend on a synergistic 
effect of a direct mitogenic and antiapoptotic stimulation of endothelial cells as 
well as the autocrine and paracrine cytokine secretion (Resto-Ruiz et al. 2002). 
The angiogenic stimulation of B. henselae occurs through at least two 
apparently distinct pathways such as secretion of factor stimulating Ca2 
signaling (McCord et al. 2007) and activation of proinflammatory pathways 
involving NF-kB (Kempf et al. 2005). Furthermore, the angiogenic 
reprogramming of host cells infected with B. henselae seem to be regulated by 
the activation of HIF-1, a transcriptional factor that stimulates angiogenesis 
and secretion of vascular endothelial growth factor (VEGF). The secretion of 
HIF-1 and VEGF has been demonstrated in patients with bacillary 
angiomatosis and in vitro system (Kempf et al. 2005, Riess et al. 2004). There 
are still many controversies regarding endothelial proliferation stimulated by B. 
henselae because some studies support that direct contact with the pathogen is 
necessary for proliferation while other evidences underline that endothelial 
cells can also proliferate separated from bacteria. In additions, it was found that 
B. henselae increases survival of endothelial cells through inhibition of 
apoptosis mediated by caspases 3 and 8 (Kirby and Nekorchuk 2002) (Figure 
5). 
Although, a strong transcriptional reprogramming of endothelial cells after B. 
henselae occurs, these cells do not secrete significant amount of  VEGF (Dehio 
2005; Kempf et al. 2005). Therefore, VEGF detected in lesions angiomatosis 
perhaps can be released by other cells such as macrophages supporting the 
hypothesis of a paracrine effect on the endothelial cell proliferation (Resto-
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Ruiz et al. 2002). Indeed, endothelial cells incubated with supernatants of B. 
henselae-infected macrophages have showed an increased rate of proliferation 
through both release of VEGF and pro-angiogenic factors including IL-1 or 
IL-8 (Resto-Ruiz et al. 2002, McCord et al. 2005). However, massive secretion 
of IL-8, a pro-angiogenic cytokine was detected in endothelial cells after B. 
henselae-infection, by acting through an autocrine mechanism (McCord et al. 
2006). However, this paracrine stimulation can trigger the secretion of various 
proangiogenic and antiapoptotic factors, especially IL-8 and monocyte 
chemoattractant protein 1 in endothelial cells, thus promoting the migration of 
cells and the angiogenic process (McCord et al. 2005) (Figure 5). 
  
 
 
Figure 5. Representation of vascular tumorigenesis due to B. henselae. 1) 
Inhibition of endothelial cells apoptosis. 2-3) Secretion of angiogenic factors 
from endothelial cells acting on endothelial cells by autocrine manner. 4-5) 
Induction of adhesion and secretion of chemoattractant molecules. 6) VEGF 
secretion from macrophages. 7) inhibition of apoptosis. 8) Release of 
endothelial cell mitogens (modified by Pullianiem et al 2012). 
 
1.2.5 Mechanisms of immune evasion of B. henselae 
 
The intracellular persistence of B. henselae in host erythrocytes depends 
on the efficient ability to subvert and to evade the innate and adaptive host 
immune responses. After the entry of B. henselae in the host, the pattern 
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recognition receptors on the professional phagocytes play a crucial role in the 
recognition of pathogen. Lipopolysaccharide is an essential outer membrane 
component in Gram-negative bacteria that with the lipid A portion  recognized 
by a subgroup of pattern recognition receptors, the Toll-like receptors, triggers 
the secretion of pro-inflammatory cytokines and recruitment of inflammatory 
cells (Miller et al. 2005). The lipopolysaccharide of  B. henselae is composed 
of a unique combination of Lipid A and an uncommon hydroxylated long-
chain fatty acid with an unusual structure that might explain the weak Toll-like 
receptors  activation and its less toxicity that promotes the persistent infection 
and the evasion of immune system (Zähringer et al. 2004). In addition, B. 
henselae resides in membrane-bound intracellular compartments of 
macrophages and endothelial cells, rather than in the cytoplasm. However, 
BCVs have showed a delayed development or complete lack of typical 
endocytic markers allowing to the pathogen of avoid lysosomal fusion and 
acidification of vacuoles (Kyme et al. 2005). B. henselae have the ability to 
escape from professional phagocyte recognition likely by inhibiting the 
production of reactive oxygen species, that represents the most important 
antimicrobial effector mechanisms of these cells. 
Furthermore, it was found that B. henselae can avoid to elicit the host immune 
response also through an immunomodulation mechanism. Several studies in 
vitro have demonstrated the involvement of Th1 response in B. henselae 
infection showing an increase of cytokine IFN, IL-12 and IL-8. In particular, 
in immunocompetent subjects, acute B. henselae infection causes an 
upregulation of pro-inflammatory such as IL-2 and IL-6 and anti-inflammatory 
cytokines including IL-10 (Kabeya et al. 2009). Upregulation of IL-2 can 
induce a T-cell response in immunocompetent subjects by helping to explain 
the increased susceptibility of immunocompromised individuals to B. henselae 
infection. Also IL-6 is a marker of inflammation and it is crucial in the 
induction of an effective immune response. Moreover, IL-10 is a potent anti-
inflammatory mediator that controls the cellular immune response to B. 
henselae and its  levels correlate strongly with IL-6 levels by suggesting that 
IL-10 might control the cytokine cascade, perhaps as a protective mechanism 
(Papadopoulos et al. 2001, Vermi et al. 2006). This cytokine acts as 
immunomodulator, being able to suppress the function of several immune cells 
including T helper, monocytes, macrophages influencing both innate and 
adaptive immune response. It was proposed that the level of IL-10 may pose a 
balance between a condition favorable both to the host, by preventing tissue 
damage and to bacteria by attenuating the immune response. 
 
1.3.0 Primary niches other than endothelial cells 
 
Although several studies have highlighted the main pathogenic 
mechanisms of B. henselae infection (Schülein et al 2001, Dehio 2008, 
Okujava et al. 2014), to date, it is still unclear what is the primary niche of this 
bacterium in vivo.  
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Due to the demonstrated in vivo intraerythrocitic presence of B. henselae, the 
HPCs have been assumed as potential niche and cause of persistent and 
recurrent intraerythrocitic bacteremia (Eicher et al. 2012). Mandle (2005) has 
found that B. henselae not infects human erythrocytes in vitro likely due to the 
lack 1-integrin required for bacterium binding. Conversely, the infection of 
CD34
+
 HPCs with B. henselae results in the presence of the pathogen in 
erytroid cells associated with the persistence and the replication of B. henselae 
in host progenitors cells during differentiation of these cells. The proliferation 
of HPC infected has been lower respect to cells not infected and HPCs infected 
have shown an increased secretion of IL-8 that promotes the mobilization of 
HPCs and thus the propagation and systemic diffusion of pathogen from the 
bone marrow. Noteworthy, the infection of HPCs results in the diffusion of 
bacterium through differentiated cells. Moreover, the HPC mobilized can 
promote the B. henselae infection of other organs such as endhotelium and they 
can be a vehicle to carry B. henselae in the sites where vasoproliferative 
disorders occur. Interestingly, HPCs were resistant to Listeria monocytogenes, 
Salmonella enteritica and Yersinia enterocolitica infection in vitro (Mandle et 
al. 2005).  
Salvatore (2008) has demonstrated for the first time that B. henselae can be 
adhere to and invade human EPCs in vivo and in vitro (Salvatore et al. 2008). 
 
1.3.1 Endothelial progenitor cells 
 
EPCs were derived from bone marrow and incorporated into foci of 
physiological or pathological neovascularization. (Shi et al. 1998; Asahara et 
al. 1999). These cells have characteristics similar to hematopoietic stem cells 
due to the common progenitor, the hemangioblast and they are able to 
differentiate ex vivo in cells with endothelial phenotype. Most of the EPCs 
reside in the bone marrow in close association with the hematopoietic stem and 
stromal cells, that provide the optimal microenvironment for hematopoiesis. 
Many studies have shown that heterologous, homologous or autologous EPCs 
are incorporated in the sites of angiogenesis in animal models of ischemia 
(Asahara et al 1999). Shi (1998) has identified the presence of EPCs derived 
from bone marrow in the adult peripheral blood, by demonstrating the presence 
of a subpopulation able to move through the blood stream in all vascular 
districts (Shi et al. 1998). Originally, the postnatal neovascularization was  
promoted by a mechanism of angiogenesis due to in situ proliferation and 
migration of existing endothelial cells. However, the finding that EPCs can 
home to sites of neovascularization and differentiate into endothelial cells in 
situ is consistent with the vasculogenesis process, a critical paradigm well 
described for the embryonic neovascularization but also proposed for the adult 
organism (Rafii et al. 2003, Napoli et al. 2007). Therefore, these studies have 
revolutionized the idea that postnatal tissue revascularization was achieved by 
neighbouring endothelial replication and that the differentiation of 
hemangioblast in vascular endothelial cells occurs only during the embryonic 
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stage (Napoli et al. 2007, Urbich et al. 2004). EPCs are immature cells that can 
contribute to the postnatal neovasculogenesis (Rafii et al. 2003, Napoli et al. 
2007). Numerous studies have described their stem cell features, their pattern 
of surface proteins including CD133, VEGFR-2, CD34 and their involvement 
in physiological as well as pathological neo-vascularisation (Rafii et al. 2002). 
EPCs are recruited from the bone marrow to sites of hypoxia through a 
mechanism mediated by HIF and VEGF where can differentiate into 
endothelial cells and promote the formation of new vessels (Brixius et al. 
2006).  
 
1.3.1 EPCs and cardiovascular regeneration 
 
EPCs represent the promoters of vascular repair and a protective factor 
against cardiovascular disease, acting both at a very early stage of the 
atherogenesis process and in the final stage of clinical manifestations (Napoli 
et al. 2011). The negative correlation between cardiovascular risk and the 
number of circulating EPCs is reinforced by the finding that exposure to certain 
drugs that favorably affect the cardiovascular risk results in a positive 
modulation of the number and function of EPCs (Dotsenko 2010, Vasa et al. 
2001, Dimmeler et al.  2001). Indeed, after endothelial dysfunction the EPCs 
are incorporated in the area of vascular damage by supplying endothelial cells 
for new blood vessels growth and by stimulating the secretion of growth 
factors. In normal conditions, the endothelium produces and secretes 
substances that modulate vascular tone and protect the endothelium (Napoli et 
al. 2011). The loss of structural and functional endothelium triggers complex 
events that lead to atherosclerosis and cardiovascular diseases, such as 
myocardial infarction, heart failure and peripheral artery disease. Several 
studies have focused on the EPC number and their involvement in several 
human pathologies. In particular, the crucial role of EPCs in neovascularization 
opens new perspectives in the clinical setting, which include either the 
revascularization after ischemia or viceversa the inhibition of vasculogenesis in 
oncology (Napoli et al. 2011). The number of EPCs has been reported to 
negatively correlate with several risk factors for cardiovascular disease such as 
hypertension and diabetes mellitus (Umemura and Higashi 2008). Levels of 
EPCs are inversely correlated to progression of coronary artery disease 
(Liguori et al.  2010). Indeed, the number of EPCs is known to decrease with 
increasing age associate with a telomere length (Napoli et al. 2007). Changes in 
EPC number have been also investigated in metabolic disorders (Fadini et al. 
2009),  neoplastic pathologies (Naik et al. 2008), chronic kidney disease (Jie et 
al. 2010) and chronic obstructive pulmonary disease (Janssen et al. 2014). 
Furthermore, increased levels of EPCs have also been associated with other 
inflammatory conditions such as periodontal infections, rheumatoid arthritis or 
in situations of acute tissue damage (Napoli et al. 2011). 
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1.3.2 Identification and characterization of EPCs 
 
Asahara (1997) has described the EPCs after isolation of CD34
+
 cells 
from human peripheral blood using magnetic microbeads (Asahara et al. 1997). 
These cells after plating on fibronectin-coated surfaces have shown endothelial 
characteristics and positivity for both the binding to lectin and the 
incorporation of acetylated low density lipoprotein (Asahara et al. 1999). The 
EPC differentiation was associated with progressive modification of surface 
marker expression. Several studies have identified three markers characterizing 
functional endothelial precursor cell: CD133, CD34, and the vascular 
endothelial growth factor receptor (VEGFR-2), also termed kinase insert 
domain receptor (KDR) or fetal liver kinase (Flk-1) (Gehling et al. 2000, 
Peichev et al. 2000). The CD34 antigen is a marker not exclusive of 
hematopoietic stem cells because it was found at extremely low concentrations 
on mature endothelial cells. CD133 is an early hematopoietic stem cell marker 
expressed on hematopoietic stem and on progenitor cells from human bone 
marrow but it is missing on mature endothelial cells and monocytes and it is an 
important marker for the identification of  EPCs (Handgretinger et al. 2003). 
The number of CD133 cells in non mobilized peripheral blood has been 
reported to be in the range of 0.002% from total peripheral mononuclear cells, 
but the stimulation with granulocyte colony stimulating factor causes an 5-fold 
to 10-fold increase in vivo (Peichev et al. 2000). CD133-positive cells are able 
to differentiate in vitro in endothelial cells in the presence of VEGF and other 
growth factors and a small subset of CD34
+
 cells from different sources 
express both CD133 and VEGFR-2 markers (Gehling et al. 2000). In the bone 
marrow, early progenitor and endothelial phenotype cells that express 
CD133/CD34/VEGFR2 but not vascular endothelial (VE-) cadherin and von 
Willebrand factor are localized (Yoder 2012). Conversely, in the peripheral 
blood early EPCs express CD34, CD133 and the VEGFR-2 while the late 
EPCs lost CD133 and began to express endothelial lineage cell markers such as 
von Willebrand factor, endothelial nitric oxide synthase and Ve-cadherin 
(Figure 6 and Table 1). Early and late EPCs are characterized by different 
proliferation potential. Indeed, the early-EPCs show a low proliferative ability, 
appear within 4-7 days of culture with a spindle-shaped and express CD14 
(monocytic marker) and CD45 (pan-leukocytic) antigens. Late-EPCs develop 
after 2-3 weeks of culture, express the endothelial nitric oxide synthase and 
display a higher proliferative potential compared to early-EPCs (Resch et al. 
2012, Yoder 2013, Basile et al. 2014). Mature endothelial cells of large vessels 
are negative for CD34 and express high amounts of VEGFR-2, VE-cadherin, 
and von Willebrand factor. CD133 is not detectable on the surface of mature 
human endothelial cells and monocytic cells (Casamassimi et al. 2007).  
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Figure 6. From bone marrow to blood circulation of EPCs. Differential 
expression of markers during the mobilitation and maturation of EPCs. 
 
 
Table 1. Phenotipic characterization of EPCs. 
CELLS SITE OF LOCALIZATION MARKERS 
BM-EPC Bone marrow CD133
+
, CD34
+
, VEGFR-2
+
 
“Early” EPC Peripheral blood 
CD133
+/-
, CD34
+
,VEGFR-2
+ 
CD31
+
, 
 
CD14
+
, VE-Caderine
+
, vWF
+
 
“Late” EPC Peripheral blood 
CD34
+
,VEGFR-2
+
,CD31
+
, VE-
Caderine
+
, von Willebrand factor +, 
endothelial nitric oxide synthase 
 
1.3.3 EPCs and B. henselae 
 
Salvatore (2008) has demonstrated for the first time that B. henselae can 
adhere and invade human EPCs both in vivo and in vitro (Figure 7) (Salvatore 
et al. 2008). The in vitro assays have revealed that the infection of EPCs with 
B. henselae impairs functional activity and significantly reduces the number of 
these cells. B. henselae adheres to EPCs through cytoplasm protrusions of cell 
membrane followed by internalization of bacteria detectable in vacuoles. EPCs 
infected show a changed cell morphology with mitochondria disruption and 
expansion of endoplasmatic reticulum. Interestingly, the treatment of EPCs 
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with L-arginine results in a reduced number of intracellular invasomes, intact 
cytoplasmatic mithocondria and a reduced expansion of smooth endoplasmatic 
reticulum. Taken together, these results support the concept that, like HPCs, 
EPCs can carry B. henselae in other organs such as endothelium in which the 
vasoproliferative disorders occur with the involvement of several pathways 
including immune response genes and de-regulation of inflammatory gene 
networks (Salvatore et al. 2008, Costa et al. 2010). Moreover, EPCs of Down 
syndrome patients have shown a higher susceptibility to infection with B. 
henselae compared to euploid cells as well as a reduced number and altered 
morphology, thereby confirming the angiogenesis and immune response deficit 
observed in Down syndrome individuals (Costa et al. 2010). 
In a recent study, in order to evaluate the effect in vivo of B. henselae, a murine 
model of infection was used (Sommese et al. 2012). The authors have 
evaluated the effects in vivo and in vitro of coinfection between B. henselae 
and another gram negative bacterium, Bacteroides fragilis. B. fragilis is a 
component of the gut microflora of most mammals that mediates its effects 
through the capsular polysaccharide (PSA). B. fragils and the mutant PSA 
that lack PSA component, are able to infect human EPCs in vitro. However, in 
the early EPCs coinfected with both bacteria, B. fragilis competes with B. 
henselae and it impairs the  infection with B. henselae. Conversely, in the 
coinfection with B. fragilis PSA the presence of B. henselae in EPCs is more 
relevant. Thus, B. fragilis and B. fragilis PSA are both able to infect human 
EPCs but the presence of the PSA is necessary in order to compete with B. 
henselae internalization. The infection with B. henselae causes a drastic 
reduction of EPCs in mice. This reduction can be prevented in mice coinfected 
with B. fragilis but not with B. fragilis PSA (Sommese et al. 2012).  
 
 
Figure 7. Representative images by immunofluorescence. Confocal image of 
human EPCs uninfected (A) and B. henselae infected (B) (by courtesy Dr. A. 
Casamassimi). 
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1.4.0 HLA and infections 
 
The susceptibility to infections and to several human diseases such as 
diabetes and heart diseases depends to a complex interaction between 
environmental and host genetic factors. In particular, the genes involved in the 
immune response reflect the evolutionary advantages of a diverse 
immunological response to a wide range of infectious pathogens and they can 
contribute to the susceptibility to human diseases (Alves et al. 2006). Recently, 
there has been much interest in the genetic markers that through the interaction 
with other factors can influence the immune response to an infectious disease. 
Moreover, infectious agents are able to cause different immune response in 
different infected individuals (Bleckwell et al. 2009). In general, many genetic 
loci can influence the susceptibility or the resistence to infectious disease 
including the Human Leukocyte Antigens (HLA) system. During the immune 
response versus a pathogen, the HLA molecules must link the peptides derived 
from the pathogen and the repertoire of T cells that can be triggered by this 
HLA-peptide association (Klein and Sato 2000). 
 
1.4.1 Organization of HLA complex 
 
HLA complex is located on the short arm of chromosome 6 and 
contains a large number of genes that are divided in three classes. HLA class I 
and class II molecules are controlled by two different regions highly complex 
and polymorphic, including multiple loci and different alleles. HLA class I 
includes the molecules HLA-A, -B,-C, while HLA class II the molecules HLA-
DR,-DQ and –DP, the HLA class III does not encodes HLA molecules (Klein 
and Sato 2000) (Figure 8). 
HLA class I and II regions are components of the immune response with a high 
polymorphism. Indeed, there are currently 12,672 HLA alleles described by the 
HLA nomenclature at all loci, included in the IMGT/HLA Database and 
recognized in the official sequences for the WHO Nomenclature Committee for 
factors. In particular, about 9000 different alleles are recognized for class I and 
3000 for the class II. HLA genes are closely related and are inherited in a 
Mendelian manner as haplotype from each parent (Table 2). 
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Figure 8. Classical scheme of HLA complex on chromosome 6. HLA class I 
region includes HLA-A,B,C genes, while class II the HLA-DR,DQ. 
 
HLA class I molecules are expressed on the surface of all nucleated cells, class 
II molecules are expressed on B cells, antigen-presenting cells and T cells 
activated. HLA class I antigens are heterodimeric molecules divided in three 
regions. The extracellular region shows three domains (1, 2 and 3) and the 
high polymorphic 1 and 2 domains contain variable amino-acid sequences 
and are the site of peptide-binding domains.  
Class II molecules consist of two trans-membrane polypeptides,  and  chains 
and the high polymorphism of these molecules occur mostly in  chain than . 
The domain 1 and 2 form an antigen-binding groove (Figure 9). 
The class I and II molecules bind different peptides. In particular, class I-
restricted T cells recognize endogenous antigens including cellular, 
transformed or pathogen proteins and the complex HLA molecule-peptide are 
recognized by T-cells receptor of CD8
+
 cells. Conversely, class II molecules 
recognize extracellular exogenous proteins after endocytosis and degradation 
and are recognized by T-cell receptor of CD4
+
 cells. The HLA antigens are 
characterized at serological level, by identifying the class I antigens on the T 
cells isolated from peripheral blood lymphocytes and the class II antigens on 
the B cells. However, the serologically indistinguishable variants of HLA 
antigens, due to few amino-acid substitutions are identified at molecular level 
(Klein and Sato 2000). 
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Figure 9. Structural organization of HLA class I and II molecules. Class I 
molecules consists of the trans-membrane polypeptide while Class II molecules 
consist of two trans-membrane polypeptides,  and  chains 
 
The high polymorphism of HLA complex is localized in the antigen-binding 
groove, indeed some variations of amino-acids can affect the peptide-binding 
specificity of HLA molecules. In the different populations and geographic 
regions there are a different distribution and frequency of HLA molecules due 
to the function of these molecules of to present infectious agents. To date, the 
number of known alleles increase thank to the modern molecular techniques of 
sequence-based typing. Several new alleles are detected in the exons encoding 
the domain that present the antigens but also in others intron or exon domains 
(Table 2). 
 
Table 2. The most important HLA-A, B and C loci involved in the self/no-self 
recognition and in the immune response and the related antigen and allele 
numbers. 
Loci N° antigens N° alleles 
HLA class I 
HLA-A 24 2995 
HLA-B 49 3760 
HLA class II HLA-DR 20 1700 
 
1.4.2 Effect of HLA polymorphism on infectious disease 
 
The polymorphic HLA alleles can promote the genetic diversity and the 
variable susceptibility of the different individuals to the diseases. The HLA 
molecules are involved in the presentation of antigens and for this reason, 
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individuals presenting a certain combination of HLA alleles that not binds in a 
proper manner to antigens or that not triggers an adequate response will be less 
suitable to resist to the pathogens. The HLA alleles that provide protection are 
able to select and stimulate immune cells in order to destroy the infected cells. 
A positive or negative genetic correlation between classical HLA loci and 
major infectious disease was found. Some of these associations have been 
investigated by showing a strong correlation, while others not much. The 
interaction between factors involved in immune response to infection including 
the intensity of the infection or the function of T cells and genetic factors such 
as HLA complex can determine the evolution of the disease (Alves 2006). 
Different mechanisms of HLA/disease association were proposed such as the 
greater or less affinity between a particular HLA molecule and the peptide. In 
addition, the HLA antigens can act as receptors for pathogens by promoting or 
avoiding the cell entry. HLA can influence the process of thymic selection by 
promoting the tolerance of T cells versus the pathogens due to a molecular 
mimetism between pathogens and host antigens (Kulkarni et al. 2008). 
Numerous evidences are focused on the association between HLA and viral 
infections such as HCV, HBV and HIV demonstrating a protective or the 
causative role of some HLA molecules versus the onset of viral infections 
(Elahi and Horton 2012, Grimaldi et al. 2013). However, the association 
between HLA and mycobacterial, bacterial and parasitic infections has been 
reported and emphasized (Blackwell et al. 2009, Alves et al. 2006). Several 
studies have demonstrated an association between mycobacterial infections and 
HLA. The consensus in the literature is that HLA-DRB1*15, HLA-DRB1*16 
and HLA-DR3 are associated with the tuberculoid leprosy form while HLA-
DQB1*01 is associated with the lepromatous leprosy form. Moreover, it was 
found that HLA-DRB1*15 allele is associated with a severe form of 
tubercolosis and with the drug-resistant, while a protective association was 
observed between some form of leprosy and HLA-DQB1*02 (de Souza-
Santana et al. 2015). Mohammed (2014) has reported a high HLA frequency of 
B*18 and DRB1*01 and a decrease of B*51 in patients with mycobacterium 
tuberculosis infection (Mohammed et al. 2014). The association of bacterial 
infection with ankylosing spondylitis, anterior uveitis is common. It was found 
that Klebsiella antigens are similar to HLA-B27 antigens and through a 
mimetism mechanism they can promote the ankylosing spondylitis onset as 
well as the age and the frequency at which it occurs (Shamji et al. 2008). In 
patients with anterior uveitis, the association between Gram-negative bacteria 
including Serratia, Salmonella and B. henselae and HLA-B*27 was described. 
In addition, an association with HLA-DR antigens in patients negative for 
HLA-B27 it was found. Furthermore, Chlamydia, Ureoplasma, Shigella 
infection are related to HLA-B27, HLA-B51 and HLA-B35. High IgG levels 
antibody against B. henselae was identified in patients with uveitis B-27 
positive. Kerkhoff (2000) has reported the frequency of HLA-B27 in patients 
with uveitis and serological characteristics of acute infection with B. henselae 
(Kerkhoff and Rothova 2000).  
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2. Aim of the study 
 
Infectious complications represent a significant source of morbidity and 
mortality in HTx recipients. However, the importance of infection in post-
transplantation time it is well know whereas there are few studies evaluating 
the incidence and the types of infection in patients awaiting HTx and the 
impact on the early post-transplantation period when the immunosuppressive 
therapy predisposes the patients to infectious complications. These infections 
are due to pathogens that rarely cause infection in immunocompetent 
individuals and can be difficult to identify, to treat, and can be lethal in the 
immunosuppressed patients. Most post-transplantation infections represent 
reactivation of latent or quiescent infections that had been contracted prior the 
transplantation. Recently, several papers have showed the incidence of B. 
henselae infections in solid organ transplantation recipients, where these 
bacteria cause a disseminated infection with involvement of different organs 
mainly due to vasoproliferative lesions. Furthermore, in vitro and in vivo 
studies data have demonstrated that isolated EPCs are able to internalize B. 
henselae. Susceptibility to infections depends on the complex interaction of 
environmental and host genetic factors such as the HLA molecules. Many 
studies have demonstrated a statistical association between HLA class I and II 
molecules and susceptibility or protection to a range of complex infectious 
diseases and most of these studies have used a case-control approach.  
This study aims to evaluate in patients awaiting HTx enrolled in the Regional 
Reference Laboratory of Transplant Immunology of Second University of 
Naples, the seroprevalence of B. henselae, the quantitative analysis of EPC 
cells and the correlation between  B. henselae prevalence and HLA antigens.   
Moreover, in order to investigate this unique human pathology, we evaluate the 
effects of B. henselae infection in an immunocompromised murine model by 
analyzing the tissue damage and the number of EPC circulating. 
Immunocompromised mice can represent a useful model in order to evaluate 
the B. henselae infection because patients awaiting transplantation will be 
underwent immunosuppressive therapy in the post-transplantation time. 
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3. Materials and Methods 
 
3.1 Patients and controls  
 
Patients were enrolled at the Laboratory of Transplant Immunology of 
Second University of Naples and, serum samples of 38 patients awaiting HTx 
and of 50 volunteers (control group) were collected. EDTA-blood was obtained 
from all control subjects and patients. Following blood collection, sera were 
separated by centrifugation and stored at -20°C. The patients selected and 
enrolled in the waiting list for HTx have severe symptoms of heart failure, 
angina or rhythm disturbances intractable and they are in severe clinical 
conditions (ejection fraction < 30% and peak oxygen consumption max < 8 
ml/kg/min) with no alternative form of treatment available, other than a HTx. 
Once a patient with severe congestive heart failure has been identified as 
having a limited life expectancy and severely impaired quality of life, cardiac 
transplantation should be considered. Irreversible pulmonary hypertension, 
active infection and cancer are criteria that can prevent a person from being 
eligible for transplantationation 
Exclusion criteria for control group were any clinical history of 
lymphadenopathy and/or fever in the last 6 months. Patients and controls were 
normalized for cat exposure. None of individuals included in this study 
presented clinical symptoms. Written informed consent was obtained from 
patients and volunteers according to the Declaration of Helsinki. 
 
3.2 Serological testing for B. henselae antibody detection 
 
A commercially available Bartonella Indirect Immunofluorescent 
Assay (IFA) (Focus Diagnostics, Cypress, California, U.S.A.) was used to 
assess the qualitative detection and semi-quantitation of human serum IgM and 
IgG antibodies to B. henselae and B. quintana according to manufacturer’s 
instructions. In the first stage, suitable dilutions of patient sera were added to 
appropriate slide wells in contact with the substrate for IgM and IgG, 
respectively. In the second stage, fluorescein-labeled antibody to IgM or IgG, 
was added, respectively. After the slide was washed, dried, and mounted, it 
was examined by fluorescence microscopy (Zeiss West, Germany) at 
magnifications of 40X and 100X. Each kit included positive and negative 
controls. Positive reactions appeared as bright apple-green fluorescent bacteria. 
According to the recommendations of the manufacturer titers from 1:20 for 
IgM and 1:64 for IgG were considered positive. 
 
3.3 Serological and molecular HLA typing 
 
All patients were tested for HLA class I (HLA-A and -B) and class II (-
DR) loci by serological and molecular HLA typing. The serological test was 
performed by standard complement-dependent microlymphocytotoxicity assay  
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Mononuclear cells of both patients and control group were isolated from 
peripheral blood using magnetic monodisperse microspheres (Dynabeads TM-
Invitrogen, Italy) coated with monoclonal antibodies specific for isolation of B 
and T lymphocytes. The cells, attached to the microspheres, were subsequently 
used in HLA typing plates with acridin orange/ethidium bromide to stain viable 
and dead cells. Genomic DNA was extracted from whole peripheral EDTA 
anticoagulated blood by commercial DNA isolation kit (Promega, Italy). 
Molecular typing was carried out by Sequence-Specific Primed PCR (PCR-
SSP) method using a micro SSP-HLA A-B-DR generic DNA typing tray 
(Olerup SSP ABDR, Biospa, Italy). All patients are typed only for HLA- A-B-
DR loci at 2 digit. According to the manufacturer’s instructions, the PCR was 
performed by using the Gene Amp PCR system 9700 (Applied Biosystems, 
Foster City CA, USA). The PCR products were separated on 2% agarose gel 
containing ethidium bromide and visualized under ultraviolet (UV) light. 
(Grimaldi V 2013). 
 
3.4 Flow cytometry detection of human circulating EPCs 
 
The total number of circulating EPCs was analyzed by flow cytometry 
(Casamassimi 2007). 100l of EDTA-blood samples of controls and patients 
were incubated 30 minutes in the dark with the following antibody 
combinations: phycoerythrin (PE)-conjugate-anti-CD133\2 and Allocyanin-
conjugated (APC)- anti-KDR-2 (Miltenyl Biotec, Gerrmany). A fluorescent 
isotype identical antibody control was added to the blood sample and incubated 
in the dark at room temperature for 15 minutes. Red blood cells were lysed by 
the addition of 2 ml of Pharmalyse TM solution (BD sciences) followed by 
incubation in the dark at room temperature for 15 min. FACS analysis was 
performed using BD FACSAnto II and data analyzed using DIVA software. 
Each analysis includes n°10000 events in the lymphocyte region. Three 
samples replicates from each patient were analyzed and the average was 
performed. 
 
3.5 Bacterial strains, growth conditions and mice infection 
 
The B. henselae strain ATCC49882 (LGC Promochem) was stored at -
80°C in tryptone soya broth (TSB) until use and grown on Columbia agar with 
5% defrinated sheep blood at 37°C and with 5% of CO2. 
SCID/Beige 8 weeks of age, were purchased from Charles River Laboratory.. 
Mice were infected with B. henselae via intraperitoneal route at dose of 10
9
 
CFU/mouse suspended in TSB. Control mice were injected with the same 
medium in the absence of bacteria. Following infection, mice were observed 
daily for signs of illness. After 36 days of infection, blood was withdrawn by 
cardiac puncture before sacrifice and collected in heparinized tubes. At the 
times of euthanasia, liver, spleen and aorta were excised and fixed for 
microscopic analysis. 
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3.6 Histopathology 
 
All samples (liver, spleen and aorta) for immunohistochemistry were 
fixed in formaldehyde (4%), embedded in paraffin and sliced into 5 mm thick 
sections were cut; one slide was stained with haematoxylin-eosin and the 
remaining were used for IHC analyses, Masson Trichome and Warthin-starry 
stain using standard protocols (Sommese 2012, Chiaroviglio 2010). After de-
paraffinization, slides containing two serial sections were processed for heat-
induced epitope retrieval. When cooled, slides were washed in PBS and then 
incubated for 609 at 37uC with the primary antibody. Arterial segments, livers 
and spleens were stained with a mouse monoclonal antibody anti-B. henselae 
diluted 1/100 (Novus Biologicals). After a further wash in PBS, sections were 
incubated with the secondary antibody biotinylated for 15 minutes at 37°C. 
 
3.7 Transmission Electron Microscopy  
 
The aorta and liver tissues were cut into 1 mm3 blocks and fixed in 
1.5% glutaraldehyde in 0,067 M cacodylate buffer at pH 7.4 (Wisse et al. 
2010). The samples were left in fixative for 3 h at 4°C and then washed in 
0,134 M cacodylate buffer, pH 7.4, at 4°C. Then they were post-fixed in 1% 
osmium tetroxide in 0,067 M cacodylate buffer, pH 7.4, at 4°C for 1 h and after 
washed in 0,134 M cacodylate buffer, pH 7.4, at 4°C. Fixed tissues were 
dehydrated in ascending series of ethyl alcohol and then embedded in epon. 
Semi-thin (1,5 mm) sections of transmission electron microscopy embedded 
liver and aorta samples were cut with a glass knife for light microscopic 
observations. Sections were stained with 1% toluidine blue solution prepared in 
1% sodium tetraborate buffer. Ultra-thin (50–80 nm) section were cut and 
stained first with uranyl acetate 3% in 50% ethyl alcohol and then with 2,6% 
lead citrate. These sections, loaded on 200 mesh grids, were observed in a 
JEM-1011 (JEOL) transmission electron microscope at 100 kV. 
 
3.8 EPC number in infected mice 
 
A single blood aliquot was collected by cardiac puncture from the 
ventricle under anaesthesia, with Tribromoethanol 240 mg/Kg, using 
appropriate size needles and collected into heparin-coated tubes. A volume of 
100 l of blood was incubated for 30 minutes at 4°C with Fluorescein 
isothiocyanate (FITC)-conjugated monoclonal antibody PE-anti-Sca-1 
(phycoerythrin-conjugated stem cell antigen-1) and APC-anti-Flk-1 
(allophycocyaninconjugated fetal liver kinase-1) (BD Pharmingen). After 
incubation, erythrocytes were lysed using FACS lysing solution (Becton-
Dickinson) 2 ml for each tube for 10 minutes at room temperature at dark. 
After the lysis, two washes were performed with PBS by centrifugation at 1900 
rpm for 10 minutes. Isotype-identical IgG antibodies were used as controls (BD 
Pharmingen). The samples were analyzed on a FACScan (Becton-Dickinson) 
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using DIVA software. Each analysis included approximately 10000 events, 
referred to the total number of white cells. The samples were analyzed in 
duplicate 
3.9  Data analysis 
 
The baseline clinical and laboratory characteristics of the patients in the 
two groups were compared with continuous variables evaluated using a one-
way ANOVA and categorical variables were analyzed using the Chi square.  
Statistical analysis of HLA typing was carried out by SPSS (statistical package 
of social science) version 17 (SPSS Inc., Chicago, IL, USA). Data were 
expressed in terms of frequencies and percentage. Chi square  was used as a 
significance test for comparison between the study groups. Multiple logistic 
regression analysis was used to evaluate HLA alleles associated with B. 
henselae infection. In the model statistically significant variables were included 
in univariate analysis. Odds Ratio (OR) and 95% Confidence Interval (CI) 
were calculated. Significance was considered when p value was less than 0.05.  
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4. Results 
4.1.1 Clinical data 
 
In order to evaluate the seroprevalence of B. henseale in patients 
awaiting HTx respect to a control population represented by volunteers, 
enrolled at the Laboratory of Transplant Immunology of Second University of 
Naples, we have collected sera of 38 patients and 50 controls. All the subjects 
analyzed living in Campania Region. 
The patients selected and enrolled in the waiting list for HTx have severe 
symptoms of heart failure, angina or rhythm disturbances intractable and they 
are in severe clinical conditions (ejection fraction < 30% and peak oxygen 
consumption max<8 ml/kg/min) with no alternative form of treatment 
available, other than a HTx. Indeed, once a patient with severe congestive heart 
failure has been identified as having a limited life expectancy and severely 
impaired quality of life, HTx should be considered. Irreversible pulmonary 
hypertension, active infection and cancer are criteria that can prevent a person 
from being eligible for transplantation. 
In Table 3 we reported the baseline demoghraphic and clinical characteristics  
of study subjects. 
 
Table 3: Baseline data of patients awaiting HTx 
Gender, n (%)  
   Male 28 (73.7) 
   Female 10 (26.3) 
Age, y 52±16 
Cardiac disease, n (%)  
   No-ischemic DCM 21 (55.3) 
   Ischemic DCM 17 (44.7) 
Valve implant, n (%)  
   Yes 6 (15.8) 
   No 32 (84.2) 
Diabetes,  n (%)  
   Yes 7 (18.4) 
   No 31 (81.6) 
Hypercolesterolemia,  n (%)  
   Yes 19 (50) 
   No 19 (50) 
Hypertension, n (%)  
   Yes 10 (26.3) 
   No 28 (73.7) 
Statin use, n (%)  
   Yes 19 (50) 
   No 19 (50) 
Renal failure, n (%) 
    Yes 18 (47) 
   No 20 (53) 
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In particular, the patients enrolled in waiting list for HTx were affected by 
ischemic or no-ischemic dilated cardiomyopathy (DCM), 55.3% and 44.7% 
patients, respectively. The mean age of the 38 study patients (28 male and 10 
female) was 52±16 years. The 15,8% of patients present cardiac valve 
implantations, the 18,4% are affected by diabetes, the 50% of patients had 
incidence of hypercholesterolemia and the 10% of patients had hypertension. 
The mean age of control population (30 male and 20 female) was 38±8 years. 
 
4.1.2 Serological analysis of B. henselae antibody 
 
Serum samples of 38 patients awaiting HTx and 50 healthy donors were 
examined by IFA. In our study, we have found a B. henselae antibody 
significant positivity rate of 21% (n=8) in patients awaiting HTx (p=0.002) 
(Table 4). Moreover, in our patients the seroprevalence of B. henselae was not 
significantly associated with age, gender, ischemic and non-ischemic DCM and 
other clinical parameters (p>0.05). The differences in comorbidity between 
cases and controls were statistically different (1.41±0.96 vs 0.42±0.32; 
p=0.001). Moreover, the age of the patients in waiting list for HTx was higher 
than control group (52.1±17.0 vs 38.8; p=0.001). The prevalence of 
comorbidities evaluated (dilated cardiomyopathy, valve disease, renal failure, 
diabetes, and hypertension) and the differences between cases and controls  are 
reported in Table 4.  
 
Table 4 Seroprevalence of B. henselae in patients awaiting with advanced 
heart failure awaiting HTx and in control subjects  
Variables Patients # 38 Controls # 50 p 
Age (years) 52.1±17.0 38.0±8.0 0.001 
Comorbidity 1.41±0.96 0.42±0.32 0.001 
B. henselae antibodies (%) 21 0 0.002 
Valve Diseasee (%) 16.2 2.0 0.016 
Previous myocardial infarction (%) 37.8 0 0.001 
Diabetes (%) 18.9 0 0.001 
Hypertension (%) 24.3 8 0.005 
Renal Failure (%) 47.1 0 0.000 
 
In detail, we found a positive rate of 8% (p>0.05) for IgM antibody against B. 
henselae and a significant value of 13% (p=0.02) for IgG antibody. All the 
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controls analyzed are resulted negative both for IgM and IgG antibodies 
against B. henselae. 
In Table 5, we report in detail the B. henselae seropositivity rate of patients 
awaiting HTx (n=8) that are resulted positive to IgM or IgG antibodies. The 
highest antibody dilution with a positive reaction was indicated. We found a 
positive rate of 8% (n=3 patients) with p>0.05 for IgM antibodies, while a 
significant value was found for IgG with 13% (n=5 patients) of positivity 
(p=0.02). According to the recommendations of the manufacturer and to the 
literature data, titers from 1:20 for IgM and 1:64 for IgG were considered 
positive. In Table 5, also demograpich and clinical characteristics of patients 
are reported. All controls resulted negative for both IgM and IgG antibodies 
and they have shown only a low percentage of hypertension and mitral 
prolapsed.  
 
The Fig. 10 reports the representative IFA images of one patient resulted 
positive to B. henselae IgG (A) and a negative control of B. henselae IgG (B). 
None of individuals included in this study showed positive reactions to B. 
quintana. All patients positive for IgG and IgM antibodies, were monitored at 
least twice at different sampling times confirming the result. In particular, we 
have also found in the live patient positive for IgM, reported in the last line of 
Table 5, after two months of positivity for IgM the seroconversion of 
antibodies in IgG with titre of 1:64.  
 
 
Table 5 Seropositivity of B. henselae IgM and IgG antibodies in patients 
awaiting HTx 
Gender Age 
IgM anti-
B. 
henselae 
IgG anti-
B. 
henselae 
Heart disease 
DCM 
Valve  Diabete 
Hyper- 
cholesterolemia 
Hypertension Transfusion 
F 8 // 1:128 no-ischemic  Yes No No No Yes 
M 64 1:20 // ischemic  No Yes Yes Yes No 
M 50 // 1:128 ischemic  No No Yes Yes No 
M 67 // 1:64 ischemic  No No Yes No Yes 
M 55 // 1:64 no-ischemic  Yes No No No No 
M 33 1:20 // ischemic  No No Yes No Yes 
M 66 // 1:64 ischemic  No No Yes Yes No 
F 56    1:20  // no-ischemic  No No No No No 
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Figure 10 Immunofluorescent assay images. (A) Serum sample of one patient 
awaiting HTx positive to B. henselae IgG, magnification 100X; (B) negative 
control of B. henselae IgG supplied by the manufacturer, magnification 40X. 
(in collaboration with Dr. C. Pagliuca). 
 
4.2 Circulating EPC detection 
 
The detection of EPCs in peripheral blood samples has been performed 
by flow cytometry analysis that represents the gold standard for this aim 
because it is a method simple and reproducible. At this regard, based on the 
description of EPCs, a combination of markers including at least a marker of 
stemness usually CD133 and a marker of endothelial commitment such as 
KDR (also known as VEGFR-2 and Flk-1) were used. In particular, an 
phycoerythrin (PE)-conjugate-anti-CD133 and an allophycocyanin (APC)-
conjugated KDR were used. Each analysis included 10.000 events. EPCs are 
defined as double-positive CD133
+
/KDR
+
. 
The numbers of circulating EPCs were gates with lymphocytes as indicated by 
the arrow in the inserted forward and sideward scatter plot image in figure 
11A. We used an isotype control in which no positive events are obtained in 
Q2-1 area (Figure 11B). In the figure 11C we reported a representative sample 
with double-positive marked cells in the Q2-1 area corresponding to EPCs. 
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Figure 11. Example of forward and sideward scatter plot image cytometric 
analysis for the assessment of EPCs. Delineation of the population 
lymphocytes (A) in the sample, as indicated by an arrow. 
Representative identification of subpopulation in the sample marked with the 
isotype control (B) and  with CD133
+
/KDR
+
 (C).  
 
EPC circulating number has shown a decrease of 20% in patients awaiting HTx 
B. henselae-negative respect to control group, whose EPC number was 
considered 100% (1.0) but this difference is not significant (p>0.05). The 
number of EPCs in patients B. henselae-positive was further reduced respect to 
control (42%). Interestingly, EPCs number were significantly lower in patients 
with B. henselae-positive patients respect to negative (p <0.05) with a 
reduction of 22% (Figure 12). 
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Figure 12. EPC number in control group, B. henselae negative and B. henselae 
positive patients. EPC number was measured by FACS analysis. 
KDR+/CD133+ double positive cells were considered as human EPCs 
(*p<0.05). 
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4.3 Distribution of HLA-A,-B,-DR alleles in patients awaiting HTxat and 
association with B. henselae infection 
 
The possible association between HLA class I and class II alleles and B. 
henselae infection were assessed by comparing the frequencies of these alleles 
in two groups of patients, negative and positive for B. henselae. 
We have performed a serological and molecular typing at low resolution of 
HLA-A, B and –DR loci of all patients awaiting HTx enrolled in our study. 
The serological typing allows to identify the HLA antigens expressed on the 
membrane of T and/or B cells, while the molecular typing identified all the 
alleles HLA including the antigens that are null and for this reason not 
expressed or expressed at low levels on the cell membrane.  
The distribution of HLA-A* alleles among all Bartonella-positive patients 
versus Bartonella-negative patients is reported in Table 6A. 
 
Table 6 A. Comparison of HLA-A* frequencies between B. henselae negative patients 
versus positive patients 
HLA 
B. henselae 
negative   patients 
(30) 
B. henselae 
positive patients 
(8) OR 95% CI p 
N % N % 
A*01 7 23,3 1 12,5 0,47 0,05 4,50 0,51 
A*02 9 30,0 4 50,0 2,33 0,48 11,45 0,30 
A*03 7 23,3 3 37,5 1,97 0,37 10,40 0,42 
A*11 4 13,3 2 25,0 2,17 0,32 14,71 0,43 
A*23 1 3,3 1 12,5 4,14 0,23 74,70 0,34 
A*24 10 33,3 1 12,5 0,29 0,03 2,65 0,27 
A*26 3 10,0 1 12,5 1,29 0,12 14,33 0,84 
A*29 4 13,3 1 12,5 0,93 0,09 9,69 0,95 
A*30 6 20,0 0 - - - - - 
A*32 3 10,0 1 12,5 1,29 0,12 14,33 0,84 
A*33 2 6,7 0 - - - - - 
A*69 1 3,3 0 - - - - - 
OR=odds ratio; CI=confidence interval. *p<0.05 is significant 
 
Among B. henselae-negative patients, the most frequent HLA-A* allele is 
A*24, while in the group of positive patients the most frequent is A*02, but no 
statistical significance was found between HLA-A* and B. henselae infection. 
The distribution of HLA-B* alleles among all B. henselae-positive patients 
versus B. henselae-negative patients is reported in Table 6 B. 
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Table 6 B. Comparison of HLA-B* frequencies between B. henselae negative 
patients versus positive patients 
HLA 
B. henselae 
negative patients 
(30) 
B. henselae 
positive patients 
(8) 
OR 95% CI p 
 N % N %    
B*07 3 10,0 0 - ND - ND 
B*08 4 13,3 0 - ND - ND 
B*13 2 6,7 0 - ND - ND 
B*14 1 3,3 0 - ND - ND 
B*15 4 13,3 1 12,5 0,93 0,09-9,69 0,95 
B*18 8 26,6 1 12,5 0,39 0,04-3,71 0,41 
B*35 6 20,0 5 62,5 6,67 1,23-36,05 0,03 
B*37 1 3,3 0 - ND - ND 
B*38 1 3,3 0 - ND - ND 
B*39 3 10,0 0 - ND - ND 
B*40 1 3,3 1 12,5 4,14 0,23-74,70 0,34 
B*41 2 6,7 0 - ND - ND 
B*44 3 10,0 2 25,0 3,00 0,41-22,08 0,28 
B*45 1 3,3 0 - ND - ND 
B*49 2 6,7 1 12,5 2,00 0,16-25,34 0,59 
B*50 2 6,7 0 - ND - ND 
B*51 5 16,7 2 25,0 1,67 0,26-10,77 0,59 
B*52 2 6,7 0 - ND - ND 
B*55 2 6,7 0 - ND - ND 
B*58 3 10,0 1 12,5 1,29 0,12-14,33 0,84 
       OR=odds ratio; CI=confidence interval. *p<0.05 is significant 
Among B. henselae-negative patients, the most frequent HLA-B* allele is 
B*18, while in the group of positive patients the most frequent allele is B*35. 
Interestingly, in univariate analysis HLA-B*35 allele results more frequent in 
B. henselae-positive patients compared to negative group (OR 6.67; 95% 
CI=1.23-36.05; p=0.03). 
The distribution of HLA-DRB1* alleles among all B. henselae-positive 
patients versus B. henselae-negative patients is reported in Table 6 C. 
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Table 6 C. Comparison of HLA-DRB1* frequencies between B. henselae-
negative patients versus positive patients 
HLA 
B. henselae negative 
patients (30) 
B. henselae positive 
patients (8) 
OR 95% CI p 
 N % N %    
DRB1*01 0 - 1 12,5 ND - ND 
DRB1*03 6 20,0 0 - ND - ND 
DRB1*07 9 30,0 2 25,0 0,78 0,13-4,62 0,78 
DRB1*08 5 16,7 0 - ND - ND 
DRB1*09 0 - 1 12,5 ND - ND 
DRB1*11 14 46,7 8 100,0 ND - ND 
DRB1*12 1 3,3 1 12,5 4,14 0,23-74,70 0,34 
DRB1*13 4 13,3 1 12,5 0,93 0,09-9,69 0,95 
DRB1*14 2 6,7 0 - ND - ND 
DRB1*15 1 3,3 1 12,5 4,14 0,23-74,70 0,34 
DRB1*16 7 23,3 0 - ND - ND 
OR=odds ratio; CI=confidence interval. *p<0.05 is significant 
 
Among all patients the allele HLA-DRB1*11 is the alleles most frequent in 
both group of patients and no significant association was found with infection. 
A multiple logistic regression model, including age, gender, cardiac diagnosis 
of ischemic and no-ischemic DCM and significant HLA variables, confirms 
that a significant risk of B. henseale infection is present in patients with HLA-
B*35 (OR=7.62; 95% CI=1.27-45,60; p=0.026). (Table 6 D.) 
 
 
 
Table 6 D. Multiple logistic regression analysis of 
variables  associated with B. henselae infection 
Variables OR 95% CI P value 
Age 0,99 0,94-1,05 0,740 
Gender 1,20 0,12-11,58 0,876 
HLA-B*35 7,62 1,27-45,60 0,026 
Diagnosis 0,58 0,08-4,48 0,603 
OR=odds ratio; CI=confidence interval. *p<0.05 is significant 
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4.4 Pathogenic effects of B. henselae infection in immunodeficient mice 
 
4.4.1 Mice infection 
 
We have developed a immunodeficient mouse model of B. henselae 
infection to investigate the effects of infection and to provide a model for 
human disease in immundeficient host including transplanted patients. 
Three SCID/Beige mice were infected with 10
9
 CFU/mouse suspended in TSB 
via intraperitoneal. No animals died after infection and all animals were 
observed and monitored during the 36 days of infection. 
 
4.4.2 Morphological analysis of mice tissues. 
 
Morphological study was performed by hematoxylin-eosin staining to 
evaluate the morphology and the inflammatory infiltrate and Masson 
Trichomic staining to differentiate the collagen. In the liver of uninfected mice, 
the morphological study have evidenced absence of inflammatory infiltrate and 
supporting collagen in the area of the portal triad. In animal infected with B. 
henselae we have observed the presence of moderate/severe inflammatory 
infiltrate as revealed by hematoxylin-eosin staining and increased of fibrosis 
with collagen-deposition in the area of the portal triad as showed by Masson 
Tricomic staining (Figure 13). The assessment of periportal and 
intraparenchymal inflammatory infiltrate was performed semiquantitatively 
(absent, mild, moderate and severe), the same parameters were used to evaluate 
the fibrosis. The same analysis were performed on the spleen of the two groups 
of animals. Morphological analysis showed an increase of fibrosis and 
deposition of collagen fibers in the subcapsular region, intracapsular and 
perivascular in mice infected with B. henselae (Figure 14).  
In the aorta, we observed no significant differences in the intima, media and 
adventitia layers in the uninfected and B. henselae infected mice. In mice B. 
henselae infected we have found a small increase of collagen deposition in the 
adventitia and intima layers (Figure 15). 
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Figure 13. Representative microscope image of hematoxylin-eosin (A-D) and 
Trichrome staining (E, F) of liver tissue. Absence of inflammatory infiltrate in 
the area of the portal triad of uninfected mice at x10 (A) and x20 magnification 
(B) with absence or a minimal amount of supporting fibrocollagen (E, at x 20 
magnification). Presence of moderate/severe inflammatory infiltrate in the area 
of the portal triad of B. henselae infected mice at x10 (C) and x20 (D) 
magnification. Increase of fibrosis in the area of the portal triad in B. henselae 
infected mice (F x10), (in collaboration with Dott.ssa G. Mansueto). 
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Figure 14. Representative image of hematoxylin-eosin (A-C) and Trichrome 
staining (D-F) of spleen tissue. Absence in the spleen of uninfected mice of 
collagen deposition (A, hematoxylin-eosin x4 magnification and D, Masson 
Thricomic x20 magnification). Significant increase of subcapsular, 
intracapsular and perivascular deposition of collagen in B. henselae infected 
mice (B, C hematoxylin/eosin x4 and x10 magnification and E, F Masson 
Thricomic x20 and x63 magnification), (in collaboration with Dott.ssa G. 
Mansueto). 
 
48 
 
 
Figure 15. Representative microscope image of hematoxylin-eosin (A-B) and 
Trichrome staining (C-F) of aorta. Normal structure of intima and adventitia 
layers of aorta of uninfected mice (A, hematoxylin/eosin x10 magnification, C, 
E Masson Thricomic x4 and x40 magnification). Small increase of collagen 
deposition in the intima and adventitia of B. henselae infected mice (B 
hematoxylin/eosin x10 magnification, D, F Masson thricomic x10 and x40 
magnification) (in collaboration with Dott.ssa G. Mansueto). 
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The lesions were further characterized using anti-Bartonella specific antibody 
and the Warthin-Starry stain, preferentially used for CSD diagnosis, in order to 
identify the presence of bacteria in the damaged tissues. We have identify the 
presence of bacteria in the liver and spleen of infected mice as reported in 
Figure 16 and 17. 
 
 
Figure 16. Immunohistochemistry analysis of liver samples of uninfected (A, 
x100 magnification) and B. henselae infected (B, x20 magnification) mice with 
an antibody against B. henselae showing the presence of organisms in infected 
samples. Warthin-Starry stain of uninfected (C, x20 magnification) and 
infected mice (D, x20 magnification and E, x100 magnification) showing the 
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presence of organisms surrounding the vessel and invading into the lumen of 
sinusoid (in collaboration with Dott.ssa G. Mansueto). 
 
 
Figure 17. Immunohistochemistry analysis of spleen samples of uninfected (A, 
x100) and B. henselae infected mice (B, x100 magnification) with an antibody 
against B. henselae. Warthin-Starry stain of uninfected mice (C x100 
magnification) and B. henselae infected (D x100 magnification) showing the 
presence of organisms present also in small aggregates (in collaboration with 
Dott.ssa G. Mansueto). 
 
In order to confirm these results we have performed also a morphological 
analysis with blue of toluidine staining in liver and aorta of uninfected and B. 
henselae infected mice. We have found a normal portal triad in two groups of 
mice but in B. henselae infected mice a consistent collagen deposition was 
observed in the region surrounding the periportal and centrilobular veins 
(Figure 18). In the aorta of uninfected and B. henselae infected mice, we have 
observed a regular structure of the intima, the innermost layer, of the media, 
the middle layer with muscle and elastic fibers, and of the adventitia, the outer 
layer, that provides additional support and structure to the aorta. However, the 
intima layer of infected mice was resulted thicker than control mice (Figure 
19). 
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Figure 18. Figure 6. Section of the liver stained with toluidine blue of SCID 
mice uninfected (A) and B. henselae infected (B,C). (A) Regular hepatic portal 
vein (v), bile duct (db) and epithelial cells. (B, C) Regular structure of hepatic 
portal vein with hepatic artery (a), bile ductal (db) and portal vein but with 
consistent collagen (B, C) and presence of fibroblast (with Dott.ssa B. 
Avallone e Dr R. Cerciello). 
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Figure 19. Section of the aorta stained with toluidine blue of SCID mice 
uninfected (A) and B. henselae infected (B). Normal aorta intima with 
endothelial cells, media with muscle and elastic fibres and adventitia with  
collagen (A). Intima layer appears thicker than control (arrow) while media and 
adventita layers appear regular (in collaboration with Dott.ssa B. Avallone e Dr 
R. Cerciello). 
 
4.4.3 Ultrastructural analysis 
 
The ultrastructural analysis with transmission electron microscopy 
performed on the liver of uninfected mice revealed a regular architecture of 
hepatic tissue with typical portal triad characterized by a small bile duct and 
portal vein with hepatocytes showing the polygonal shape, rounded nucleus 
with peripheral heterochromatin and massive presence of mitochondria and 
peroxisomes. The liver of B. henselae infected mice have shown macroareas 
with abundant collagen with the characteristic banding pattern under the 
endothelium of  the portal vein with fibroblasts and myeloid cells. We have 
found also the presence of bacteria embedded in the collagen fibres and in 
space of Disse (Figure 20).  
The same ultrastructural analysis were performed on aorta of uninfected and B. 
henselae infected mice. Aorta of all samples analyzed have shown any 
morphological alteration. In particular, in uninfected mice, the intima layer is 
regularly constituted by endothelial cells adherent to the basement membrane 
with elongated nucleus and peripheral heterochromatin. The tunica media 
constituted by muscle cells with elongated and longitudinal arrangement and 
with alternating elastic fibers. Finally, the adventitia composed of fibrocytes 
and collagen bundles with typical banding pattern (Figure 21). However, in B. 
henselae infected mice we have found that the layer of endothelium is thicker 
respect to control mice.  
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Figure 20. Ultrastructural analysis of liver of SCID mouse  uninfected (A) and 
B. henseale infected (B-D). (A) portal triad characterized by a small bile duct 
(db) and  portal vein (v) with hepatocytes with the characteristic polygonal 
shape, rounded nucleus with peripheral heterochromatin and massive presence 
of mitochondria and peroxisomes; (B) macroareas with abundant collagen 
under the endothelium of  the portal vein (v) with fibroblasts (f) and myeloid 
cells (m); (C) macroareas with collagen (c) and fibroblasts with characteristic 
stellate shapes (f); (D). Magnification of collagen bundles (c) with the 
characteristic banding pattern. B. henselae bacterium embedded in area of 
collagen (E) and in the space of Disse (F) (in collaboration with Dott.ssa B. 
Avallone e Dr R. Cerciello).  
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Figure 21. Ultrastructural analysis of the aorta of SCID mouse (A, B) control 
and infected with B. henselae (C, D). In both mice analyzed, the adventitia (A, 
C), the outer layer that provides additional support and structure to the aorta 
appears regular with fibroblasts (f) and collagen fibres (c). The intima of both 
uninfected and infected mice, the innermost layer of the vessel, appears 
regularly constituted by a monolayer of endothelial cells in direct contact with 
the blood and with a basal membrane. The tunica media is regular with smooth 
muscle cells and elastic fibers (B, D), but in B. henselae infected mice (D), the 
layer of endothelium is thicker respect to uninfected mice (in collaboration 
with Dott.ssa B. Avallone e Dr R. Cerciello).  
  
4.4.4 EPC number in infected mice 
 
After 36 days of infection, before the sacrifice, blood of mice was 
collected in order to evaluate whether the EPC number in 
immunocompromised mice was influenced by B. henselae infection. We have 
performed a cytofluorimetric assessment of EPC number using PE-anti-Sca-1 
(phycoerythrin-conjugated stem cell antigen-1) and APC-anti-Flk-1 
(allophycocyanin-conjugated fetal liver kinase-1) antibodies.  
The mean number of EPCs were measured as cells double-positive for both 
Flk-1 and Sca-1 (Flk-1+/Sca-1+). As shown in Figure 22, the number of EPCs 
was found significantly increased in mice infected with B. henselae (1,4) 
compare to the uninfected group, whose the EPC number was considered as 
100% (1.0).  
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Figure 22. EPC number in uninfected and B. henselae-infected mice. EPC 
relative number of infected mice versus control was measured by FACS 
analysis. Sca-I/Flk-I double positive cells were considered as murine EPCs 
(*p<0.05).  
0,0 
0,2 
0,4 
0,6 
0,8 
1,0 
1,2 
1,4 
1,6 
Uninfected mice B. henselae infected mice 
EP
C
 r
e
la
ti
ve
 n
u
m
b
e
r 
 
* 
56 
 
5. Discussion 
 
The results of our research established for the first time: a 21% of B. 
henselae seropositivity in patients awaiting HTx, an impairment of EPC 
number in B. henselae-infected patients and a correlation between B. henselae 
infection and the presence of HLA-B*35 allele in our patients. Furthermore, 
we have evaluated the tissue damage induced by B. henselae in a model of 
immunodeficient mice in which we also observed a significantly increase of 
the number of circulating EPCs. 
The overall prevalence of B. henselae seropositivity was of 21% (n=8) in 
patients awaiting HTx (p=0.002). In particular, we have found that 8% of 
patients were positive for IgM (p=0.14) and 13% were positive for IgG 
antibodies (p=0.02). To our knowledge, this is the first report on the 
seroprevalence of B. henselae on patients awaiting HTx in our Region and in 
Italy. Our analysis supports the hypothesis that the age is a significant factor 
associated with prevalence of B. henselae infection in the patient population. 
Indeed, patients are older than controls and, likely they had more years of 
possible exposure to infective agents. However, in our population, this factor 
together with the state of general impairment of these patients due to the severe 
heart failure, likely increases the prevalence/incidence of infection. In post 
transplantation time, under the influence of immunosuppressive therapy these 
patients are at risk of developing infection diseases (Toyoda et al. 2013, 
Crudele et al. 2011). Despite significant advances in the management of solid 
organ transplantation, the infections still remain a considerable factor 
influencing transplantation outcome (Toyoda et al. 2013). Although in the post-
transplantation period, many risk factors for infection are known, the 
epidemiology of infections in patients awaiting HTx and the effect of pre-
transplantation infections in the post-transplantation period remain to be 
investigated (González-Padilla et al. 2013). Most of the guidelines for pre-
transplantation management recommend the screening of patients potentially 
exposed to infectious agents, but they do not include opportunistic pathogens 
such as B. henselae (Fischer and Avery 2009). However, candidates awaiting 
HTx may have infections, caused by coagulase-negative staphylococci and 
aerobic gram-negative bacilli due to ventricular assist device implantations that 
are utilized as a bridge to transplantation or for the setting of congestive heart 
failure and general impairment.  
Bartonella infections display different progression and organ involvement due 
to a balance between host and bacterial factors (Mogollon-Pasapera et al. 
2009). Recently, several reports described cases of solid organ transplantation 
recipients who developed disseminated infections due to B. henselae. (Psarros 
et al. 2012, Rostad et al. 2012, Moulin et al. 2012). Cases of bartonellosis have 
been reported in liver, heart, kidney and lung transplantations and with a 
percentage of 28% of cases in subjects aged under 18 years (Poudel et al. 
2014). Interestingly, the pathological lesions appear granulomatous as well as 
suppurative and the vasoproliferative disorders occur in lymph nodes, liver and 
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spleen. B. henseale infection in kidney recipients has been associated with 
acute rejection episode (Dharnidharka et al. 2002). The mechanism by which 
B. henselae causes vasoproliferation in immunocompromised hosts is still 
unclear, however, it has been demonstrated the ability of B. henselae to induce 
proliferation of endothelial cells. One hypothesis is that, in an 
immunocompromised host, the vasoproliferation bacterial-induced can 
overwhelm the granuloma formation, typical response of the 
immunocompetent individuals. The granuloma in immunocompetent subjects 
can limit the infection to the same lymph node region through a localized B-
cell immune response regulated by dendritic cells that control the systemic 
spread of pathogens and represent a mechanism of effector phase of the 
immune response. In immunocompromised hosts, Bartonella bacteremia can 
occur followed by spreading of bacilli to liver, spleen, and cardiac valve 
triggering the vasoproliferative lesions as bacillary peliosis and/or bacillary 
angiomatosis (Vermi et al. 2006). Noteworthy, the most immunosuppressive 
drugs used in transplanted recipients, including cyclosporine and tacrolimus, 
target the cell-mediated immune response especially the T-cells leading to 
decrease the numbers of activated T cells. For this reason, the formation of 
granuloma that requires multiple factors such as T cells, might be impaired in 
the transplanted patients, thus promoting a switch versus vasoproliferative 
disorders (Rostad et al. 2012, Bonatti et al. 2006). However, at present there 
are no clear relashionship between the development of disseminated 
bartonellosis and any specific immnosuppressive regimen. In the transplanted 
patients, serological tests were useful diagnostic tool with a definition of a 
positive titre for IgM> 1:20 and IgG>1:64. PCR represents a diagnostic support  
that requires sample tissues but a negative result should not exclude the 
infection (Bonatti et al. 2006). Some studies support the possibility of 
Bartonella infections through blood transfusion, probably due to its intra-
erythrocytic viability during the storage at 4°C (Ruiz et al. 2012). In subjects 
who develop bartonellosis few months after transplantation, a possible via of 
transmission of B. henselae could be also the organ donor (Scolfaro et al. 
2008). Indeed, Scolfaro (2008) has reported a case of liver bartonellosis in a 
recipient whose donor was positive for B. henselae IgG antibodies (Scolfaro et 
al. 2008). Moreover, in immunocompromised patients a possible source of 
bartonellosis could be the reactivation of previous infections, although this 
complication is uncommon for bacteria (Psarros et al. 2012). At this regard, B. 
henselae may develop various processes to facilitate its uptake and permanence 
into intracellular compartment of the host cells, thus by promoting the 
reactivation (Eicher and Dehio 2012). Endothelial cells have been assumed as a 
potential niche in vivo of B. henselae and the location within these cells is also 
believed to protect this pathogen from antimicrobial agents (Harms and Dehio 
2102). Inihibition of apoptosis, together with induction of cell proliferation, are 
pivotal mechanisms that allow the permanence of B. henselae into the host 
cells by contributing to vasoproliferative disorders (Deng et al. 2012; Harms 
and Dehio, 2012, Resto-Ruiz et al. 2002). When B. henselae gains access to the 
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human circulatory system, it disseminates from the point of inoculation and 
colonizes secondary foci showing preference for highly vascularized tissues 
like heart valves, liver and spleen (Chiaraviglio et al. 2010). Immediately after 
bacteria are released into the blood stream, where they efficiently infect 
erythrocytes and also reinfect the primary niche. Moreover, several studies 
have demonstrated that an alternative niche may be represented by HSC and 
EPCs (Mandle et al. 2005, Salvatore et al. 2008). 
In our population study, we have found a reduced number of circulating EPCs 
in patients affected by advanced heart failure respect to a control population. 
Interestingly, the number of EPCs is further and significantly reduced in B. 
henselae-positive compared to B. henselae-negative patients. Obviously, our 
small clinical study cannot fully address the potential mechanisms underlying 
alteration of EPC number. However, alteration of number of EPCs has been 
described in a wide range of conditions such as cardiovascular, inflammatory, 
immune and infectious disease. Currently, EPC reduction is considered a risk 
factor that affects cardiovascular function and that promotes cardiovascular 
disease onset. Recently, it has been reported the ability of B. henselae to infect 
EPCs in vitro and in vivo (Salvatore et a. 2008, Sommese et al. 2012). Costa 
(2010) has observed a reduced number of EPCs in patients affected by Down 
Syndrome after B. henselae infection in vitro. The reduction of EPC number 
appears due to increased oxidative stress and up-regulation of angiogenesis and 
inflammation gene pathways (Costa et al. 2010). The hypothesis that infectious 
agents could impair the endothelial repair potential was reinforced by another 
study demonstrating an association between cerebral malaria and low levels of 
EPCs (Gyan et al. 2009). In patients awaiting HTx B. henselae could affect the 
proliferation of EPCs likely as result of increased metabolic demands of the 
host cells in order to cope with to bacterial infection. 
Although several studies have highlighted the main pathogenic mechanisms of 
B. henselae infection, to date it is still unclear what is the primary niche of the 
bacterium in vivo. The results of our study and published data seem to support 
the hypothesis that EPCs could represent possible candidates for primary sites 
of infection. On this basis, mobilized EPCs could carry this pathogen to other 
organs and, more important, to the endothelium of microcirculation. It is 
plausible that the colonization of EPCs by B. henselae could profoundly alter 
the maintenance of vascular homeostatis by impairing the potential of these 
cells to regenerate the endothelial layer. Moreover, we can emphasize that the 
colonization of EPCs by B. henselae could play a pivotal role in the possible 
reactivation of bacterial infection in the post-transplantation when patients will 
be receiving immunosuppressive therapy. Therefore, the evaluation of EPCs by 
B. henselae can help you understand the pathogenic mechanisms underlying 
the infection as well as the mechanisms of vasoproliferative disorders 
occurring in immunocompromised individuals, but this issue remains to be 
elucidated. Therefore, in post-transplantation time, as a consequence of 
immunosuppressive therapy, the bacterial reactivation could result in a severe 
and disseminate bartonellosis that could compromise several organs. In 
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addition, B. henselae causes blood-culture negative endocarditis difficult to 
diagnose due to the negativity of the blood culture from native aortic valve 
tissue; this could  be the reason why most patients show heart failure especially 
after valves implantation. Recently it has been reported that HTx may be 
considered as salvage treatment in selected patients with intractable infective 
endocarditis (Meininger et al. 2001, Edouard et al. 2015). 
Therefore, we believe that an early diagnosis and an adequate treatment could 
be crucial in the pre-transplantation time in order to prevent the course of the 
disease in post-transplantation phase when the subjects will 
immunocompromised. Indeed, in patients IgG positive with current or past 
infection, the immunosuppressive therapy may exacerbate the bacterium that 
may persist in sanctuarie sites such as EPCs although patients received 
antibiotic therapy. Moreover,  B. henselae can cause sustained infections in the 
blood stream for many months, perhaps partly due its association with cells of 
sanctuaries where likely there is a hospitable environment in which it is 
protected from  the immune system.  
In our study we have found a significant association between HLA-B*35 and 
B. henselae infection in patients awaiting HTx. It is noticeable that in this study 
the B. henselae-negative patients were selected as control in order to ensure a 
similar exposure to B. henselae between case and control groups. Our results 
imply for the first time that the susceptibility to B. henselae infection is 
significantly associated with the presence of HLA-B*35 allele. Several 
infectious diseases have been associated with specific HLA alleles and the 
mechanisms underlying this association not are always clear. Knowledge of the 
mechanisms of genetic protection or susceptibility to infectious diseases could 
contribute to understanding of pathogenic or protective mechanisms of these 
processes. Furthermore, some HLA molecules may be more or less efficient in 
the presentation of bacterial epitopes to T and B lymphocytes, by affecting the 
immune response and resulting in susceptibility to infection or protection from 
pathogens. Association between HLA and B. henselae infection has been 
studied only occasionally, finding the frequency of HLA-B*27 in patients with 
uveitis and serological characteristics of acute infection with B. henselae 
(Drancourt et al. 2004, Kerkhoff and Rothova 2000). However, it is unclear 
whether B. henselae infection modifies HLA-B*27 uveitis or HLA-B*27 
positive patients are more likely to develop B. henselae infection. At this 
regard, the bacterial antigens can mimic HLA-B*27 antigen and be recognized 
as self. An association between HLA-B*35 and Clamydia pneumonia infection 
has been found in patients with coronary artery disease, showing that HLA-
B*35 is a strongest-risk gene for infection (Palikhe et al. 2008). Moreover, the 
HLA-B*35 allele has been associated with chronic hepatitis B virus, hepatitis 
C virus and cytotoxic response against Aspergillus and Mycobacterium 
tubercolosis (Hammon et al. 2005, Kim et al. 2006). Several reports have 
showed a strong association between the presence of HLA-B*35 allele and the 
HIV infection. Indeed in several populations including Italian population, the 
presence of HLA-B*35 allele confers a high risk of HIV infection and it was 
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correlated with the disease progression (Kaur and Mehra 2009). Numerous 
reports suggest that HLA class I molecules due to their ability to present the 
antigens can act as signal transducing molecules able to influence individual 
reactivity to external stimuli. The presence of the HLA-B*35 allele has 
emerged as an important risk factor for the development of isolated pulmonary 
hypertension in Italian scleroderma patients in which HLA-B*35 may 
influence the production of endothelin-1, by promoting vasoconstriction, 
smooth muscle cell hypertrophy and intimal proliferation (Santaniello et al. 
2006). The HLA-B*35 allele has been demonstrated to promote pathological 
cell activation and proliferation and gene transcription through the control of 
intracellular cation concentration in different cells (Lenna et al. 2010). It has 
been shown that B. henselae-infected host cells can induce proliferative and 
anti-apoptotic effects, through an intracellular Ca
2+
 rise from intracellular pools 
which leads to NFκB-directed pro-inflammatory activation and endothelial cell 
proliferation (McCord et al. 2007). We can hypothesized that the interaction 
between HLA-B*35 and B. henselae might influence the pathogenic 
mechanism triggered by this pathogen and HLA-B*35 could represent in our 
population a genetic marker of B. henselae infection.  
Although performed on a small number of patients enrolled in waiting list for 
HTx in our region, our study indicated that HLA-B*35 confers a B. henselae-
related risk to patients with heart failure. However, a better design and more 
patients will be needed to confirm these results in order to understand whether 
this association depend on a different ability of HLA molecules to present 
bacterial antigens to T cells or if HLA-B*35 affects the signals transduced into 
the cells such as those proliferative or apoptotic. Therefore, the different HLA 
alleles would be important factors influencing the immune responses against B. 
henselae and the outcome of the disease that should be taken into account in 
cellular-immune response studies. 
The use of systems in vitro of B. henselae infection have allowed to understand 
many of the mechanisms of Bartonella-host interaction at cellular and 
molecular level including the ability of this pathogen to induce endothelial cell 
proliferation. However, the ability of B. henselae to support a chronic infection 
and to produce its various pathological features in immunocompetent or 
immunocompromised hosts can be well understand only through an in vivo 
model. In a previous study, Sommese (2012) has demonstrated the tissue 
damage induced by B. henselae in a model of immunocompetent mice 
reporting also the internalization and colocalization of bacterium in several 
tissues. Several alterations of liver and aorta of animal infected with B. 
henselae were demonstrated compared to uninfected controls. In this system, 
the damage induced by B. henselae in liver and aorta can be prevented by the 
coinfection with B. fragilis through the PSA. The authors, for the first time  
have observed a dramatic reduction of EPCs in B. henselae-infected mice while 
the coinfection with B. fragilis has been able to restore the EPC number 
(Sommese et al. 2012). 
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In our study, we have developed a model of B. henselae infection represented 
by immunocompromised SCID\Beige mice deficient in B, T and natural killer 
cells in order to provide an experimental model for human disease in 
immunocompromised host like the transplanted patients undergo to 
immunosuppressive therapy. Our morphological and ultrastructural analysis 
performed on SCID mice infected with B. henselae showed that these mice 
tolerate infection at high concentrations as well as the human 
immunocompromised that support chronic bloostream B. henselae infection, 
with the risk of endovascular infections. Surprisingly the tolerance manifested 
by mice after 36 days of infection appears to contrast with what would be 
expected during a bacteremia with other Gram-negative pathogens where death 
would follow the infection without a rapid antibiotic therapy.  
In the tissue of B. henselae-infected mice, we have found a significant collagen 
deposition, this feature was also found in human disease such as bacillary 
angiomatosis and peliosis hepatis in which much attention is focused also on 
proliferating cell component of the response of the host (Cockerell et al. 1991; 
Borczuk et al. 1998). However, in bacillary angiomatosis, proliferating 
capillary structures have been shown embedded in an extracellular matrix 
composed by bacteria, immune cells and fibrous material (Cockerell et al. 
1991; Borczuk et al. 1998). In our study, immunohystochemistry and the 
Warthin-Starry stain used for identification of B. henselae in tissue section 
showed the presence of bacteria in the lesional areas in which they appear in 
small and large clusters and individually. This result has been confirmed by 
transmission electronic microscopy analysis that revealed the presence of 
bacteria in the collagen fibres and in space of Disse but not within endothelial 
or other cell types.  
Taking together, these observations suggest that the deposition of collagen can 
be a general pathological response to B. henselae infection, evident both in the 
tissue of immunocompromised mice models and in human lesions of bacillary 
angiomatosis and peliosis. It is possible speculate that the deposition of 
collagen allows the host to contain the pathogen but this way offers to the 
bacterium an environment where it is protected from the immune response. It is 
known that in vitro, B. henselae adheres to the collagen fibers through the 
surface adhesion molecules, this process could promote the beneficial 
association with fibers of collagen as observed in vivo (Dabo et al. 2006). The 
generalized collagen deposition, observed in our animal model, could be 
considered as a failed attempt to develop a granuloma, in an 
immunocompromised model, likely related to the time compared to infection in 
which the observation was performed. Several studies in vitro have reported 
the evidence of intracellular replication of B. henselae in erythroid and 
endothelial cells (Mandle et al. 2005, Kempf et al. 2001). In the in vivo model 
we not have observed the intracellular presence of the bacteria. Likely, B. 
henselae can replicate only in specific vascular areas that we have not 
evaluated, or the in vitro system could not reproduce the mechanisms of 
infection in vivo. Furthermore, we not have observed in immunocompromised 
62 
 
murine model the typical endothelial proliferation. Interestingly, we have 
found a significant increase of EPC number in B. henselae infected mice 
respect to control. Several stimuli can induce a mobilization of EPCs from 
bone marrow and their migration at the site of damage including HIF-1-
mediated Stromal cell-Derived Factor-1 (SDF-1) and VEGF, these two 
signaling proteins bind their respective receptors on EPCs by promoting the 
recruitment in the site of angio- and vasculogenesis (Napoli et al. 2011). The 
angiogenic reprogramming of host cells infected in vitro with B. henselae 
seems to be regulated by the activation of HIF-1 that stimulates angiogenesis 
and secretion of VEGF. The secretion of HIF-1 and VEGF have been 
demonstrated in patients with bacillary angiomatosis and in vitro system 
(Kempf et al. 2005 and Riess et al. 2004). We can hypothesize that the 
increased number of EPCs observed in  immunocompromised mice infected 
with B. henselae could be related to the onset of bacillary angiomatosis typical 
of immunocompromised subjects in which, the vasoproliferative process may 
require a great supply of endothelial precursors (Figure 23). We suppose that 
the lack of endothelial proliferation could be related to the time when we have 
performed our analysis. Furthermore, the increased EPC number in 
immunocompromised B. henselae infected mice could also represent a defense 
mechanism used by the host, considering the macrophagic features of the 
EPCs. Indeed, early-EPCs derive from a population of  CD14+ cells, and they 
are able to secrete angiogenic growth factors, thus can stimulate angiogenesis 
in a paracrine manner.  
However, further investigations should also focus on the course of infection in 
immunocompromised mice because B. henselae infection causes 
vasculoproliferative disease only in immunocompromised subjects and the 
involvement of EPCs in this process needs to be better understand. 
Interestingly, EPCs could represent a primary niche of B. henselae that can 
promote the bacterial reactivation in immunosuppression conditions but they 
could be also involved in the vasoproliferative disorders occurring in the 
immunodeficient subjects including transplanted recipients. The SCID\Beige 
mouse model used should provide an experimental basis for progress of 
understanding the pathogenesis of B. henselae infection and the immune 
response to these infections.  
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Figure 23. B. henselae and EPCs. The EPCs can internalize B. henselae, thus 
by establishing a circulating niche of this pathogen and by promoting vascular 
angiogenesis. 
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6. Conclusions 
 
We have demonstrated a high prevalence of B. henselae infection in 
patients awaiting HTx enrolled in our Regional Reference list for organ 
transplantation. We have found a significant correlation between the B. 
henselae infection and the presence of HLA-B*35 allele together with a 
significant impairment of number in circulating EPCs in patients with 
advanced heart failure. Our retrospective observational study, although 
performed on a small number of patients only in pre-transplantation time 
indicates that B. henselae, together with other emerging bacteria, should be 
included as a routine analysis in the list of opportunistic infections. Therefore, 
the pre-transplantation monitoring of B. henselae infections may be useful in 
the management of patients in post-transplantation phase when these patients 
will undergo to immunosuppressive therapy. The mechanisms underlying the 
reduction in the number of circulating EPCs (that represent an in vivo niche of 
B. henselae) might promote the bacterial reactivation. The pathophysiological 
consequences of these events in patients with heart failure as well as the HLA 
association need further investigations. 
In addition, we have evaluated the tissue damage in a model of 
immunocompromised mice by revealing a strong deposition of collagen after 
B. henselae infection and an increase of EPC number that suggest an 
involvement of these cells in the immune response of mice infected but also in 
the triggering the vasoproliferative process. However, further investigations 
should be focused on the course of infection in our patients both in the post 
transplantation time as well as in the animal model in order to understand the 
pathogenic mechanism of B. henselae. 
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